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Mutations, deletions, and epigenetic silencing of the cyclin-dependent kinase 
inhibitor p16INK4A are associated with several cancer types, but are more commonly 
associated with familial melanoma predisposition and melanoma tumors. p16INK4A 
functions as a tumor suppressor by negatively regulating the cell cycle, however several 
outstanding questions remain. It remains unclear why compromise of p16INK4A 
predisposes to melanoma over other cancers, and why several melanoma-associated 
p16INK4A mutations do not compromise CDK4-binding.  This study describes a novel 
function of p16INK4A in regulating intracellular oxidative stress independently of its role 
in cell cycle inhibition, and analyzes these functions in several familial melanoma-
associated p16INK4A point mutants.  I also demonstrate that, due in part to the pro-
oxidizing nature of melanogenesis, melanocytes have higher constitutive levels of 
intracellular reactive oxygen species (ROS) than other cell types, suggesting why genetic 
compromise of p16INK4A preferentially predisposes to melanoma. 
This dissertation demonstrates that p16INK4A was rapidly upregulated following 
ultraviolet-irradiation and H2O2-induced oxidative stress (Chapter 2).  Depletion of 
p16INK4A increased ROS and oxidative DNA damage in several cell types, which was 
exacerbated by H2O2.  Aberrant ROS levels in Cdkn2a-deficient fibroblasts were elevated 
relative to controls and normalized by expression of exogenous p16INK4A. Finally, 
p16INK4A-mediated suppression of ROS could not be attributed to the potential effects of 
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p16 on cell cycle phase. I then constructed 12 different familial melanoma-associated 
point mutants and analyzed their capacity to restore normal cell-cycle phase and ROS 
levels in p16INK4A-deficient fibroblasts (Chapter 3). Whereas wild-type p16INK4A fully 
restored both functions, various p16INK4A mutants showed different abilities to normalize 
ROS and cell cycle profiles. Different mutations were found to affect both, neither, or 
only one of the functions of p16INK4A, indicating that these two regulatory functions can 
be uncoupled. Structural analysis indicated that these distinct functions may be mediated 
by distinct regions of the protein. Lastly, in normal melanocytes, inhibition of melanin 
was sufficient to decrease levels of intracellular ROS to levels constitutively observed in 
fibroblasts (Chapter 4), indicating that the unique process of melanin production may be 
responsible for high basal levels of ROS and preferential susceptibility to oncogenic 
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Tumorigenesis Requires Several Enabling Characteristics 
The transformation of normal tissue into neoplastic tumors is thought to include a 
progressive evolution involving the acquisition of several characteristics that enable 
normal cells to become tumorigenic, and eventually, migratory and malignant.  The six 
original characteristics described as “hallmarks of cancer” (Hanahan and Weinberg 2000) 
included unregulated proliferative signaling, evasion from growth suppressors, resistance 
from cell death, and enabling replicative immortality, induction of angiogenesis, and 
activating invasion and metastasis.  Recently, two more characteristics were added that 
are involved in the development of malignancy, reprogramming of energy metabolism 
and evading immune destruction (Hanahan and Weinberg 2011).  While understanding 
the complexity of oncogenesis and the cross-talk existing between these various 
characteristics is daunting, understanding its integral factors in an organized and 
systematic fashion can potentially lead to the development of more effective and targeted 
therapies for different human malignancies. 
Reactive Oxygen Species and Genomic Instability 
The development of cancer is greatly aided by an environment that is conducive 
to the acquisition of the aforementioned characteristics.  An intracellular environment 
that enables oncogenesis is one that promotes genomic instability, a situation involving 
the generation of numerous unrepaired random mutations to a cell’s DNA.  This genomic 
instability can result in several different mutagenic outcomes, including the inactivation 
of tumor suppressor genes or the activation of oncogenes.  One potential factor that can 
lead to an environment of genomic instability is the presence of excess intracellular 
reactive oxygen species (ROS) (Waris and Ahsan 2006). 
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 Any metabolism of molecular oxygen has the potential to generate ROS such as 
the highly reactive hydroxyl radical .OH, singlet oxygen 1O2, superoxide radical O2-, or 
hydrogen peroxide H2O2 (Halliwell 1999).  ROS are produced in all aerobic cells, 
primarily during the natural process of mitochondrial respiration, and are normally tightly 
regulated by biochemical antioxidants (Nohl et al. 2003). A constitutively low level of 
intracellular ROS permits ROS intermediates to serve as second messengers in redox-
dependent signal transduction and to function in proliferation, cell cycle arrest, and cell 
death (Klein and Ackerman 2003, Scandalios 2002, Martindale and Holbrook 2002).  To 
prevent the prolonged presence of high levels of intracellular ROS, cells possess several 
antioxidant enzymes that convert highly reactive superoxide into hydrogen peroxide, 
such as mangenese superoxide dismutase (MnSOD) located in the mitochondria, and 
Copper/Zinc superoxide dismutase (Cu/ZnSOD) located in the cytoplasm (Weisiger and 
Fridovich 1973).  Hydrogen peroxide itself can then lead to increased oxidative stress 
within a cell through participation in the “Fenton reaction” or reaction with copper or iron 
ions to produce the much more reactive hydroxyl radical (Aruoma et al. 1989, Halliwell 
and Gutteridge 1990, Halliwell and Gutteridge 1992, Halliwell 1993).  The enzyme 
catalase therefore plays an important role in the decomposition of hydrogen peroxide to 
water (Waris and Ahsan 2006).  These enzymatic antioxidant systems are aided by 
nonenzymatic antioxidants that function in the thiol/disulfide system such as glutathione 
(GSH) (Droge 2002, Misra et al 2009).   
These ROS can potentially damage several different classes of cellular 
constituents.  ROS can disrupt cellular membranes by directly reacting with lipids 
(Hunkar et al. 2002), can potentially cross-link ribonucleoprotiens (Waris and Alam 
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1998), and may modify sulphhydryl groups in proteins (Knight 1995).  The accumulation 
of oxidative stress-induced damage to lipids, proteins and DNA is proposed to be a 
contributing factor in several classes of human disease, such as neurodegenerative, 
cardiovascular, metabolic, and inflammatory pathologies (Vurusaner et al. 2012).  More 
specifically, ROS and organ damage contributes to Fanconi anemia, chronic hepatitis, 
cystic fibrosis, and numerous autoimmune diseases (Takeuchi and Morimoto 1993, 
Hagen et al. 1994, Shimoda et al. 1994, Waris et al. 2005). Oxidative stress-induced 
damage to DNA has now been widely accepted as a major contributor to the onset of 
cancer (Figure 1.1) (Ames 1983, Shimoda et al. 1994).  This occurs as a result of DNA 
damage that leads to heritable changes in all cells downstream of the mutation event that 
impact the functions of the hallmarks of cancer that are believed to be crucial in the 
etiology of cancer. 
Oxidative stress can induce several types of DNA damage, such as the oxidation 
of both purines and pyrimidines, creation of alkali labile sites, and development of single 
strand breaks (Breen and Murphy 1995, Wang et al. 1998, Dizdaroglu et al. 2002), 
(Cooke et al. 2003, Jaruga et al. 2004).  DNA treated with ROS has also been observed to 
develop double tandem CC→TT substitutions, sometime refered to as thymine dimers 
(Reid and Loeb 1993).  Some of these oxidative lesions have been shown to possess 
mutagenic properties, therefore oncogenesis can potentially follow if they are not quickly 
and correctly repaired (Waris and Ahsan 2006).  Interestingly, while it has been shown 
that all four bases can potentially be modified by excessive ROS, the modification of GC 
base pairs has been shown to be much more mutagenic than AT base pair modification 







 Figure 1.1 Aberrant intracellular ROS can lead to cancer. While ROS is produced 
during normal physiological and mitogenic processes, certain exogenous events can 
overwhelm the intracellular antioxidant system and create an environment conducive to 
the damaging of different cellular constituents.  If excessive ROS damages DNA to the 









suppressor gene are G to T transversions (Brash et al. 1991, Hollstein et al. 1991, Harris 
and Hollstein 1993).  These observations have led the 8-hydroxydeoxyguanisine (8-OG) 
lesion to be the most well-studied oxidative DNA lesion. 
If not efficiently repaired, the oxidative lesion 8-OG can persist until the cell 
replicates its DNA, a time at which the replication DNA polymerases α and δ frequently 
mismatch 8-OG with Adenine (A), instead of the usual (and proper) cytosine (C) 
(Shibutani et al. 1991).  As replication of the first strand proceeds, the 8-OG then gets 
replaced by thymine (T) to properly match to the erroneous A during a subsequent round 
of DNA replication.  Therefore the net result of 8-OG persisting until DNA replication is 
the aforementioned potentially highly mutagenic GC to AT transversion (David and 
Williams 1998).  Also, high levels of intracellular oxidative stress may lead to a 
nucleotide pool that contains high levels of 8-OG that may be incorporated into DNA 
during replication (Maki and Sekiguchi 1992).  As expected, several different cancers 
commonly exhibit one or more of the following: constitutively high intracellular ROS, 
high percentages of cells that are positive for 8-OG oxidative lesions, or genetic 
compromise of hOGG1 (8-oxoguanine glycosylase 1), one of the enzymes responsible for 
repairing the 8-OG lesion (Pashaei et al. 2008), Zyrek-Betts et al. 2008).  However, much 
dispute remains in the field concerning whether this correlation is causative. 
Mammalian cells have evolved several mechanisms to deal with the presence of 
8-OG lesions, which underscores the hypothesis that this lesion poses a significant risk to 
the overall integrity of the genome (Cooke et al. 2003). The 8-OG:C pair is the substrate 
for hOGG1, which serves to free the 8-OG from double-stranded substrates using a 
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glycolytic mechanism, and relying on an internal lysine residue (Boiteux and Radicella 
2000, Bruner et al. 2000, David-Cordonnier et al. 2001).  If the 8-OG lesion has paired 
with adenine through its misincorporation into nascent DNA, it is predominantly 
removed by the glycolytic activity of hOGG2 (Hazra et al. 1998).  The adenine itself in 
the mismatched 8-OG:A pair can be removed by the MutY homologue (MYH), which 
then liberates the 8-OG base to once again attempt to correctly  pair with a cytosine 
(McGoldrick et al. 1995, Slupska et al. 1996). Nei-like glycosylase 1 (NEIL1) also 
removes 8-OG from mismatches with adenine guanine, relying on an amino-terminal 
prolyl residue rather than an internal lysyl residue like hOGG1 (Hazra et al. 2002).  
Elevated levels of 8-OG adducts have been measured in the tissues from several 
different malignancies, including breast cancer (Malins and Haimanot 1991, Nagashima 
et al. 1995), melanoma (Meyskens et al. 2001), kidney (Okamoto et al. 1994), lung 
(Vulimiri et al. 2000, Inoue et al. 1998) and hepatocellular carcinoma (Schwarz et al. 
2001).  These elevated levels of oxidative damage are thought to be mainly a result of a 
tumor environment that is constitutively high in intracellular ROS and low in antioxidant 
enzyme production (Toyokuni et al. 1995). It has been observed that several tumor lines 
that produce high levels of intracellular H2O2, even in the absence of exogenous 
stimulation, exhibit permanent activation of transcription factors and their target genes.  
This constitutively high level of ROS coupled with aberrant transcription factor activity 
may contribute to a strong selective pressure for cells that are observed in a cancerous 
malignancy.  However, to what the extent the formation of 8-OG lesions is playing a 
causative role in the development of cancer remains contested due to the existence of 
many pathologies that exhibit high levels of these oxidative lesions that do not involve 
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oncogenesis.  The presence of high levels of oxidative DNA lesions may be (at least) 
partially the result of well-established characteristics of cancer cells and their intracellular 
environments themselves, such as increased metabolic activity and increases rates of 
DNA synthesis and cell division.  More work will have to be done to mete out the details 
of the formation of oxidative lesions on the initiation and progression of carcinogenesis.  
However, it appears that oncogenesis may involve the positive selection of cells with 
constitutively high levels of intracellular ROS levels because of the acquisition of 
specific proliferative advantages and plasticity for malignant progression. 
Cell Cycle Regulation as an Oncogenic Checkpoint 
 The most fundamental trait involved with oncogenic transformation is the 
capacity of tumor cells to chronically proliferate without succumbing to the normal 
tumor-suppressive effects of cell cycle regulation.  During normal growth and 
development, the proliferative signals necessary for cell cycle progression and cell 
division are carefully regulated through cell cycle checkpoints in order to assure proper 
organismal development and tissue architecture.  Regulation of cellular proliferation is 
also imperative for continued DNA integrity and to ensure that any mutations acquired in 
the course of the pre-mitotic life of the cell are not propagated into further generations.  
This unscheduled proliferation and propagation of potentially oncogenic chromosomal 
and genomic instability is to a large extent prevented by cyclin-dependent kinases 
(CDKs) and cyclins (Malumbres and Barbacid 2005). 
 The cell cycle is made up of four distinct phases.  The first phase is called Gap 1, 
or the G1 phase.  This phase is characterized by the cell increasing in size, and passing 
through the G1 checkpoint, a mechanism by which the cell confirms that it is ready to 
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replicate its DNA.  The next phase is the synthesis, or S, phase, which involves the 
synthesis of replicated DNA.  The Gap 2 or G2 phase follows, involving continued 
growth of the cell and the passing though the G2 checkpoint that ensures that the cell is 
ready for division.  The final phase is mitosis, or the M phase, a time during which cell 
growth ceases and the majority of cellular energy is allocated to the precise division of 
the cell, a careful process mediated by the metaphase checkpoint. The progression of a 
cell through these phases is regulated by two classes of molecules, cyclins and CDKs, the 
discovery of which earned Leland H. Hartwell, R. Timothy Hunt, and Paul M. Nurse the 
2001 Nobel Prize in Physiology or Medicine (Lee and Nurse 1987) . 
 CDKs are relatively small proteins that contain little more than a kinase domain, 
and consistently weigh in the range of 30-40 kilodaltons (Lee and Nurse 1987).  These 
evolutionarily conserved proteins are found in all known eukaryotes, and interestingly 
yeast can multiply when their CDK gene has been replaced by the human gene (Lee and 
Nurse 1987).  For CDKs to impart their kinase activity and drive cell cycle progression 
they must bind to regulatory subunits called cyclins. Cyclins serve as the regulatory 
subunit and CDKs as the catalytic subunit of the activated heterodimer.  Specific cyclin-
CDK heterodimers then serve to activate or inactivate target proteins through 
phosphorylation and act as cell cycle phase checkpoints to progress the cell into proper 
entry into the next cell cycle phase.  Cells regulate the activity of individual CDK-cyclin 
complexes through the controlled synthesis and degradation of specific cyclins during 
different phases of the cell cycle, whereas CDKs are expressed at relatively constant 
levels, with most of their regulation being post translational (Figure 1.2).  CDKs are 
primarily regulated by four different mechanisms: cyclin binding, CDK-activating kinase 
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(CAK) phosphorylation, inhibitory phosphorylation, and the binding of CDK inhibitory 
proteins (CKIs) (Morgan 1995).   
The ATP-binding site of CDKs lies in a cleft formed between an amino-terminal 
lobe and a carboxy-terminal lobe (Morgan 1995).  A flexible structure called a T-loop 
blocks this cleft in the absence of cyclin binding, preventing ATP binding to the CDK.  
When a cyclin is bound to a CDK, a conformational change affects two α-helices that 
allows ATP binding and activation of the heterodimer (Morgan 1995).  The 
phosphorylation of a threonine adjacent to the active site is performed by CAK, and is 
required for full CDK activation.  Phosphorylation by CAK may occur before (as in 
yeast) or after (mammalian cells) cyclin binding.  Since CAK is not regulated by any 
known cell-cycle pathways, the limiting step for CDK activation is thought to be cyclin 
binding (Morgan 1995).  Various kinases also perform inhibitory phosphorylation on 
tyrosine and threonine residues within  CDKs, and unlike activating phosphorylation, this 
level of regulation is essential for proper cell cycle regulation. One inhibitory kinase, 
Wee 1, phosphorylates a CDK tyrosine residue and is conserved in all eukaryotes.  
Vertebrate CDKs can have threonine and tyrosine phosphorylated by membrane-
associated tyrosine/threonine protein kinase 1 (Myt1), while these residues are 
dephosphorylated by members of the cell division cycle 25 (Cdc25) family of 
phosphatases. Lastly, CDKs can be inhibited in response to toxic environmental insults or 
DNA damage through their binding to a class of proteins known as cyclin-dependent 
kinase inhibitors (CKIs).  In the presence of a sufficiently damaging insult (most often 
during the G1 phase), intracellular signals induce the upregulation of CKIs that can bind 
















Figure 1.2 Simplified representation of the cell cycle. A typical (somatic) cell cycle, 
which is divided into four sequential phases: G1, S, G2 and M. Shapes outside the cycle 






alleviated.  Animal cells contain two CKI families: the Cip/Kip family and the INK4 
family (Sherr and Roberts 1999).  Members of the INK4 family, such as p15, p16INK4A, 
p18, and p19 specifically inhibit the activity of CDK4 and CDK6, whereas Cip/Kip 
members, such as, p21, p27, and p57 inhibit a wider spectrum of cyclin–CDK complexes 
(el-Deiry et al. 1993, Gu et al. 1993, Harper et al. 1993, Polyak et al. 1994).  One of the 
INK4 proteins of particular interest to cancer researchers is p16INK4A, as it is important in 
mediating a late G1 cell cycle checkpoint and is deleted, silenced, or mutated in many 
forms of cancer, including melanoma.  Germline mutations in p16INK4A are also, for 
reasons that remain unclear, associated with a familial disposition to melanoma and 
pancreatic cancer. 
 The p16INK4a –Retinoblastoma (Rb) pathway is an important regulator of the 
G1/S transition.  Under normal growth conditions, Cyclin-dependent kinase 4/6 binds to 
cyclin D and hyperphosphorylates Rb.  While in a hypophosphorylated state, Rb is 
associated with transcription factor E2F1, keeping it inactive and thereby preventing 
transcription of E2F1 target genes necessary for transition into the S phase of the cell 
cycle.  Rb also regulates p16INK4A expression through a negative feedback loop.  
CDK4/6-mediated hyperphosphorylation of Rb leads to increased p16INK4A expression.  
This increased p16INK4A expression in turn leads to the inhibition of any further 
hyperphosphorylation of Rb, thereby decreasing p16INK4A expression.  Interestingly, 
despite the existence of this feedback loop the expression of p16INK4A has been observed 
to not dramatically change during the cell cycle to correlate with the phosphorylation 
status of Rb (Hara et al. 1996). 
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Another way by which p16INK4A provides a barrier to the emergence of 
tumorigenic cells is by inducing senescence.  The senescent state is regarded as involving 
a permanent growth arrest but cells still remain metabolically active and stable.  
Senescence was first described upon observing the lifespan of human fibroblasts in cell 
culture, but is now regarded as a more common response to certain forms of stress.  
Common characteristics of senescence include expression of senescence-associated β-
galactosidase activity, the appearance of senescence-associated heterochromatic foci, and 
an enlarged and flattened appearance of the cytoplasm (Gil and Peters 2006).  Studies in 
human fibroblasts revealed that in this system the main trigger of the start of senescence 
was the erosion of telomeres that continues with every cell division (Zindy et al. 1997).  
Eventually this shortening is interpreted as DNA damage, cell cycle arrest is triggered, 
and the p16INK4A pathway is one of several pathways that is activated.  This is evidenced 
by the observation that in many cell lines, p16INK4A expression increases with passage 
number (Zindy et al. 1997), whereas it has proven very difficult to detect during 
embryogenesis in vivo (McKeller et al. 2002, (Krishnamurthy et al. 2004, Zindy et al. 
2003, Kim et al. 2006).  Also, many immortalized cell lines show no p16INK4A expression 
due to methylation of its promoter (Ruas and Peters 1998, Sharpless and DePinho 1999). 
Biology of Melanocytes and the Danger of Melanoma  
As the largest organ of the human body, the skin is under constant bombardment 
of internal and external stimuli and therefore serves an imperative role as a barrier against 
microbial, chemical and physical exposures that could harm the body (Costin and 
Hearing 2007).  In observing nature one can see the wide array of different colors and 
patterns that most species have evolved, a result of the modulation of the distribution of 
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pigments throughout the body.  These different pigmentation patterns serve several 
purposes including heat regulation, camouflage, and cosmetic variation for mate 
acquisition.  However from an oncological standpoint the most interesting use of these 
pigments is for the defense against ultraviolet radiation (UVR) (Costin and Hearing 
2007).  In humans, melanocytes produce melanin and subsequently pass the pigment into 
their dendrites and distribute it to keratinocytes.  The melanin forms “caps” that shield 
the keratinocytes’ nuclei from the UVR, reducing the overall level of DNA damage to the 
epidermis though the conversion of UVR to relatively harmless heat energy (Fitzpatrick 
and Breathnach 1963). 
Melanocytes are highly specialized cells that produce the chemically inert and 
stable pigment melanin in membrane-bound organelles called melanosomes.  One 
melanocyte may be in contact with an average of 40 keratinocytes via its dendrites to 
pass on these melanosomes, and this melanocyte-keratinocyte unit is known as an 
“epidermal melanin unit” (Fitzpatrick and Breathnach 1963).  Melanocytes also reside in 
the middle layer (uvea) of the eye (Barden and Levine 1983), the inner ear (Markert and 
Silvers 1956), meninges (Mintz 1971), bones (Nichols et al. 1988), and heart (Theriault 
and Hurley 1970).  Melanocytes are derived from the neural crest, which during the 
second month of embryonic life forms the melanocyte precursors known as melanoblasts.  
Melanoblasts migrate through the mesenchyme and reach their target sites (Boissy and 
Nordlund 1997).  This migration and survival is contingent upon interactions between 
extracellular ligands and their corresponding receptors on the surface of the melanoblasts.  
For example, melanoblasts and melanocytes harbor the cell surface receptor KIT that 
binds to steel factor (formerly known as mast cell growth factor, KIT ligand, and/or stem 
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cell factor (SCF).  At least one type of human piebaldism is caused by a mutation in the 
KIT gene, which results in a dysfunctional KIT receptor that exhibits a decreased ability 
to bind steel factor (Bolognia 1999).  After the melanoblasts reach their destinations, they 
differentiate into melanocytes and become established at epidermal-dermal junction sites 
as early as the sixth month of fetal life (Costin and Hearing 2007). 
One way through which melanocytes produce the pigment melanin is in response 
to DNA damage that has occurred from exposure to UVB radiation (Friedmann and 
Gilchrest 1987). Melanin pigments derive from tyrosine, and occur most commonly in 
the form of black-brown eumelanin, as well as the less common red-brown form called 
pheomelanin.  Eumelanin occurs in two forms, black eumelanin and brown eumelanin, 
and both consist of a polymer of dihydroxyindole carboxylic acids and their reduced 
forms (Raper 1927). A small amount of black melanin in the absence of other pigments 
gives hair a grey color, whereas a small amount of brown eumelanin in the absence of 
other pigments causes blonde hair.  Pheomelanin forms as a polymer of cysteine-
containing benzothiazine units, and is responsible for the red-hair phenotype. 
Melanin proves to be an excellent photoprotectant because it absorbs UV 
radiation and dissipates 99.9% of its energy as harmless heat through a process called 
“ultrafast internal conversion”.  This energy conversion is responsible for the protection 
against UV-induced skin cancer, including melanoma.  Epidemiological studies have 
shown less skin cancer in individuals with higher levels of constitutive pigment and/or 
who tan well (Kollias et al. 1991, Weinstock 1993), although these studies failed to 
account for other factors important for development of skin cancer such as sensitivity to 
oxidative stress (Sander et al. 2004), sensitivity to UV-induced immunosuppression 
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(Kelly et al. 2000), and capacity to repair DNA photodamage (Gilchrest and Eller 1999, 
Sheehan et al. 2002). 
Despite its classical view as a pure photoprotectant, several studies argue that 
some intermediates in the melanin biosynthesis pathway can be harmful (Kipp and 
Young 1999, Kvam and Tyrrell 1999, Kvam and Dahle 2004).  Melanin itself can react 
with DNA and cause single-strand breaks (Marrot et al. 1999), and can produce 
intracellular ROS upon exposure to UVA radiation (Korytowski et al. 1987).  The fact 
that certain intermediate products of melanin biogenesis, such as dihydroxyindole have 
been detected in plasma and urine indicate that the highly specialized melanosome has a 
propensity to leak or rupture (Agar and Young 2005).  The tyrosinase reaction can 
produce quinones that have been found to mediate cell death at supraphysiological levels 
(Menon et al. 1983).  There is a great deal of current research involved in learning more 
about the nature of melanin as a proverbial double-edged sword; a pigment nearly 
ubiquitous in nature and evolutionarily important for the photoprotection of mankind, the 
biogenesis of which exposes cells to toxic intermediates that can induce oxidative stress, 
DNA damage, and genomic instability. 
Melanoma is the uncontrolled proliferation of the melanocytes, a specialized cell 
whose primary role is the production of melanin. Melanoma is the most aggressive form 
of skin cancer, being more metastatic than most solid tumors (it has the capability of 
becoming metastatic at a thickness as little as 1 mm), and while the rate of many cancers 
has either decreased or leveled off in recent years, melanoma occurrence continues to 
increase.  Many countries have observed a doubling in the rate of melanoma in the last 20 
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years, and a person in the United States of America is now estimated to have a 1 in 55 
lifetime chance of developing this insidious disease (Gray-Schopfer et al. 2007). 
 The problem of the increased rate of melanoma is compounded by the fact that 
there exist very few options for therapeutic intervention for the metastatic form of the 
disease.  Distant metastases cause virtually all deaths from melanoma, and melanoma 
seems especially prone to quickly spread, a problem compounded by the fact that the 
only way to prevent metastases is through surgical excision of the original tumor, and 
many patients are not seen by a physician until the primary lesion has already 
metastasized. 
 Although the early diagnoses and surgical resection of localized cutaneous tumors 
usually cures melanoma, the original lesion has a tendency to quickly progress to an 
invasive state and metastasize to the lungs, liver and brain (Bastiaannet et al. 2005, 
Buzaid 2004, Danson and Lorigan 2005).  At this point, patients generally have a five-
year survival rate of less than 10%, with a mean survival time of 6 to 12 months, and are 
commonly presented with a treatment plan that is only palliative (Tsao et al. 2004, Gray-
Schopfer et al. 2007, Balch et al. 2001, Francken et al. 2005, Bastiaannet et al. 2005).  
Patients with distant metastases respond poorly to the standard treatments with alkylating 
or cytotoxic agents, which usually results in drug resistance, melanoma relapse, and 
eventual death (Comis 1976, Hill et al. 1979, Tawbi and Buch 2010).  The dramatic pace 
at which this disease progresses underscores the urgency in the field to identify and 
functionally characterize the molecular events that initiate the oncogenic transformation 
of melanocytes into melanoma cells, and to identify pertinent genetic events that 
predispose individuals to develop this disease. 
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Development of Melanoma 
Melanoma commonly commences with the clinical presentation of benign or 
dysplastic nevi that have presented with some abnormality as defined by the “ABCDE” 
criteria (Asymmetry, irregular Border, uneven Color, Diameter greater than 
approximately 6 millimeters, and recent change or Evolution).  Perhaps the factor the 
most indicative in oncogenic transformation is any recent evolution of a nevus, which 
includes a progression into the radial growth phase.  Radial growth phase is typified by 
the lateral expansion of a nevus, while remaining localized to the epidermis (Ghosh and 
Chin 2009).  The melanocytes then may become growth factor and anchorage 
independent and invade into the upper epidermis, as well as into the dermis and 
subcutaneous tissue (Ghosh and Chin 2009).  This stage of progression is known as the 
vertical growth phase, and the thickness of this vertical growth is reported as the Breslow 
thickness (Balch et al. 2001).  The Breslow thickness is currently regarded as the most 
important marker for prognosis.  A high Breslow thickness indicates a high propensity for 
the lesion to become metastatic, first spreading to regional lymph nodes and then to distal 
sites (Ghosh and Chin 2009). 
The tendency for a localized lesion to rapidly become invasive and spread to 
distant sites necessitates the earliest possible identification and eradication of a 
potentially cancerous lesion.  A diagnosis of melanoma usually follows such imaging 
procedures as X-ray analysis, computed tomography, positron emission tomography, and 
magnetic resonance imaging (Algazi et al. 2010, Patnana et al. 2011).  Moreover, 
biopsied tumor samples can be immunohistochemically stained with known melanocytic 
markers to improve the accuracy of the diagnosis.  Such markers include S-100 and 
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melanoma-associated antigen recognized by T-cells (MART-1), also known as 
melanocyte antigen (Melan-A) (Nonaka et al. 2008, Mahmood et al. 2002, Ben-Izhak et 
al. 1994).  Melanoma can also be more accurately identified using the monoclonal 
antibody gp100 that is highly sensitive and specific for melanoma, and does not cross-
react with normal melanocytes, carcinomas or sarcomas; this allows clinicians to 
diagnose even very poorly differentiated melanoma subtypes (Mahmood et al. 2002, 
Gown et al. 1986).  Despite the benefit of these markers, there exist few clinically 
validated markers for melanoma stem cells for early, noninvasive detection of the 
disease. It is therefore of great interest to continue to discover and validate biomarkers 
consistent with melanoma initiation (Mimeault and Batra 2012). 
Targets Involved in Melanomagenesis for Therapeutical Intervention 
The dismal response rates achieved while treating metastatic malignant melanoma 
reaffirm the need for continued investigation into the complex and unique signaling 
networks that are altered in this disease.  The pace of scientific discovery and pathway 
elucidation has increased exponentially since RAS was discovered as the first melanoma 
oncogene in 1984 (Albino et al. 1984).  The discovery of RAS in this context was 
achieved through the rather laborious efforts of functional and positional cloning.  
However, recent years have ushered in the use of microarrays and high-throughput 
sequencing, aided by the Human Genome Project (Hocker et al. 2008).  Identifying 
specific genetic subsets of melanoma has and will continue to allow for more accurate 
diagnosis and selection of specific therapeutic interventions for individual patients. 
Examples of such altered pathways present in melanoma that have attracted and will 
continue to attract attention as putative therapeutic targets are the RAS-RAF-MAPK-
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ERK signaling cascade (which can be further divided into the RAS-RAF-MAPK-ERK 
signaling cascade and the PI3K-AKT-mTOR cascade) and the CDKN2A/Cyclin 
D/CDK4/6 network.  
The RAS-RAF-MAPK Signaling Cascade Is Altered and  
Activated in up to 90% of Melanomas 
As is the case for many cancers, melanocyte transformation into melanoma 
involves alterations of the specific signaling pathways involved in normal cell 
differentiation, survival, and proliferation.  Melanocytes utilize the complicated RAS 
signaling network to achieve these ends (Figure 1.3).  In 1984, transforming mutations in 
RAS (specifically neuroblastoma ras viral oncogene homolog NRAS) were first 
identified in human melanoma cell lines (Albino et al. 1984), and subsequent studies 
have identified activating NRAS mutations in 26% of sporadic melanomas (Hocker et al. 
2008). 
An aberrant activation of the RAS pathway is common to many cancer types, and 
recent technological advances have allowed the more specific identification of very 
prominent, shared mutations.  One such advance has been the description of the pathways 
of all relevant kinases involved in human cancer development, and the compilation of 
these data into the kinome.  This kinome revealed that approximately 80% of pathogenic 
changes in BRAF are found in a single codon of its kinase domain, and that this same 
codon is affected in many cancers, including melanoma (Davies et al. 2002).  This 
mutation is a 1799 T>A transition that results in a V600E amino acid change that 



























Figure 1. 3 NRAS signaling network in melanoma. Shown is a simplified diagram
of the NRAS signaling network that is mutated in up to 90% of melanomas and
benign melanocytic nevi, and commonly observed functional outcomes of pathway
activation (pink boxes). Activated AKT can also lead to increased superoxide







mutation as the most commonly mutated gene in melanoma, found to be altered in 80% 
of short-term melanoma cultures and 66% of uncultured melanoma.  The net result of 
these NRAS and BRAF mutations is a high constitutive activity of ERK, which can in 
turn lead to increased proliferation, invasiveness, angiogenesis, and metastasis (Cohen et 
al. 2002, Davies et al. 2002, Herlyn and Satyamoorthy 1996, Nikolaev et al. 2012).  
Melanoma Progression Is Promoted Through the PI3K- 
AKT-PTEN Pathway 
Another direct target of activated RAS that become constitutively activated is the 
phosphatidylinositol 3-kinase (PI3K) pathway (Figure 1.3), a signaling cascade that plays 
an integral role in regulating cellular proliferation, growth, migration and survival 
(Davies et al. 2008, Omholt et al. 2006).  The PI3K pathway activates, via 
phosphorylation, the v-akt murine thymoma viral oncogene homologs, and is negatively 
regulated by lipid phosphatase phosphatidylinositol-3,4,5 triphosphate 3-phosphatase 
(PTEN).  Common mutations therefore are seen in melanoma involving activation of the 
RAS-RAF-MAPK pathways in two different ways: either activation mutations are 
observed in NRAS or BRAF in a mutually-exclusive fashion, or the inactivation of the 
pathways negative regulator, PTEN (Tsao et al. 2000).  Interestingly, PTEN inactivation 
is observed frequently in melanomas positive for activating mutations in BRAF, but not 
NRAS.  This suggests that a synergy of activation could be occurring in the RAS pathway 
that involves the cooperation of these different types of mutations in the development of 
melanoma.  Also, activated AKT has been associated with transition from radial growth 
phase to an aggressive vertical growth phase, and this transition has been associated with 
high levels of ROS, namely superoxide (Govindarajan et al. 2007).  It is thought that 
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these high levels of superoxide are then sufficient to drive expression of NFκB, which 
then upregulates several genes thought to be essential for melanomagenesis (Figure 1.3) 
(Govindarajan et al. 2007).  Also, increased levels of phospho-AKT has been measured in 
some melanomas that were negative for activating mutations in NRAS or loss of PTEN 
activity, suggesting that additional activating genetic alterations lie upstream of AKT that 
remain to be elucidated.  
The CDKN2A/Cyclin D/CDK4/6 Tumor Suppressor Network Is Often  
Inactivated in Melanoma 
 Activating mutations in the NRAS pathway are observed in approximately 90% of 
melanoma cases, hence the emphasis that has been applied to discover and test 
therapeutic inhibitors of this pathway.  However, activating mutations in BRAF or NRAS 
alone prove insufficient to drive melanomagenesis, and oncogenic BRAF activation leads 
to a senescent state (Mooi and Peeper 2006).  This demonstrates that cells with these 
activating proliferative mutations must override the senescence program to fully achieve 
a transformed state.  The senescence program primarily involves the tumor suppressors 
RB, p16INK4a, p14ARF, and p53, therefore it stands to reason that individuals that have 
genetic compromise in one or more of these genes have an increased lifetime risk of 
developing melanoma. 
In the past it was hypothesized that critical information regarding melanoma 
susceptibility could be garnered through observing the karyotype of cultured melanocytes 
from different classes of melanocytic lesions, spanning from congenital nevi, dysplastic 
nevi, and melanoma (Cohen et al. 2002).  Most congenital and dysplastic nevi showed 
normal karyotypes, whereas all melanomas observed showed aberrant chromosomal 
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profiles.  The loss of one copy of chromosome 9 or the loss of its short arm 9p was 
observed to be the only chromosomal change common to the abnormal dysplastic 
karyotypes and the melanoma panels.  This discovery over two decades ago was the first 
to implicate a melanoma tumor suppressor(s) on 9p to be involved in the progression 
from dysplastic nevi to melanoma (Kamb et al. 1994). 
 Regions of loss-of-heterozygosity in the genomes of dysplastic nevi and 
melanoma samples were then identified in the 9p21 region through deletional analysis, 
and genetic linkage studies showed that some cases of inherited melanoma predisposition 
could be attributed to genetic compromise of this region.  Subsequent positional cloning 
efforts identified the CDKN2A locus as the area important for melanoma predisposition 
(Kamb et al. 1994, Nobori et al. 1994), as well as a locus that is deleted in pancreatic 
adenocarcinoma, glioblastoma, non-small cell lung cancer, bladder cancer, and certain 
leukemias (Kim and Sharpless 2006, Sherr 2000).  This locus is unique in that it encodes 
two separate tumor suppressor proteins, p16INK4A and Alternate Reading Frame (ARF).  
These two proteins have different first exons that are spiced to a common second and 
third exon.  Despite the sharing of the second and third exons, the p16INK4A and ARF are 
transcribed in alternate reading frames and share no amino acid homology (Figure 1.4). 
Given the complex nature of this locus, it is of great interest to researchers to 
define which protein is the most relevant for tumor suppression, and under what 
circumstances mutations in these proteins lead to cancer development. The general 
consensus concerning human tumor development is that p16INK4A is more important for  
tumor development than ARF, as somatic loss of p16INK4A without compromise of ARF 












Figure 1.4 The CDKN2A locus at chromosome 9p21. The locus has a unique 
organization, coding for tumor suppressors p16INK4A and ARF. Two separate promoters 
drive the 1β (ARF) and 1α (p16INK4A) exons, resulting in alternatively spliced transcripts 
that share exons 2 and 3. Although shared, different open reading frames within exon 2 
give rise to two distinct protein products.  P16INK4A inhibits CDK4/6-cyclin D-mediated 
hyperphosphorylation of RB; thereby, insuring that RB is in complex with the 
transcription factor E2F. RB-E2F complexes sequester factors that repress transcription, 
resulting in G1 cycle arrest. ARF blocks MDM2-mediated ubiquitylation and subsequent 
degradation of p53. This helps stabilize p53 and preserves its tumor suppressive 
activities. Loss of ARF activity can result in uncontrolled MDM2-mediated degradation 
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different germline mutations in p16INK4A that do not affect ARF have been observed in 
kindreds that present different forms of cancer in their families. (Greenblatt et al. 2003). 
The Structure of p16 and the Significance of Ankyrin Repeats 
 The structure of p16INK4A classifies it as a repeat protein, a very large group of 
proteins that consist of tandem repeating modular structures of high similarity that are 
found in many organisms that span a wide range of life forms.  These repeat proteins are 
involved in a diverse range of physiological functions such as cell cycle control, 
apoptosis, development and differentiation, vesicular trafficking, cellular scaffolding, 
cytoskeleton integrity, transcriptional regulation and cell signaling (Forrer et al. 2003), 
(Main et al. 2003).  The repeating motifs in these proteins consists of 20-40 amino acid 
residues that tend to organize themselves in a packed architecture that create a larger 
surface that forms an interface to participate in binding to other proteins (Li et al. 2006), 
(Binz and Pluckthun 2005).  In fact, concerning proteins that are involved in protein-
protein interactions only immunoglobulins are more abundant than the repeat protein 
class (Andrade et al. 2001).  Over 20 different categories of repeat proteins have been 
classified, one of the most common of which are the ankyrin repeat proteins, which 
include the melanoma susceptibility gene p16INK4A. 
Ankyrin repeat proteins consist of repeated motifs of 30-34 amino acid residues that 
serve to mediate protein-protein interactions, some of which are highly involved in the 
pathogenesis of several human diseases (Sedgwick and Smerdon 1999).  Genetic 
alterations including point mutations, methylation, and deletion of several different 
human tumors have been observed in genes encoding several different ankyrin proteins. 
While they have been understudied in the past compared to globular proteins, a recent  
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increase in the investigation of these proteins have been spurred on due to the increased 
availability of protein sequencing data that has described the commonality of these motifs 
For example, the nonredundant SMART protein database recently revealed the presence 
of 19,276 ankyrin repeat sequences in 3608 unique proteins (Mosavi et al. 2004). 
The ankyrin repeat forms a helix-loop-helix structure, with the two α-helices 
being antiparallel to each other, giving the motif the appearance of the letter L.  The β- 
hairpin loops project at roughly a 90◦ angle and form β-sheet structures with neighboring 
loops (Tevelev et al. 1996, Byeon et al. 1998).  These repeated structures will stack in a 
nearly linear fashion, and this resulting helix bundle is stabilized through both intra- and 
interrepeated hydrophobic interactions (Mosavi et al. 2004, Michaely et al. 2002).  
p16INK4A  contains four of these ankyrin repeats, flanked by flexible tails and the N- and 
C- termini (Figure 1.5).  
Dissertation Overview 
It has been well established that genetic compromise of p16INK4A is observed in a large 
numbers of tumors, with germline mutation leading to a higher predisposition to 
melanoma than other tumors.  It is currently unknown why melanocytes seem especially 
sensitive to oncogenic transformation in the context of p16INK4A inactivation or mutation.   
It has also been well established that the greatest environmental factor 
contributing to melanomagensis is exposure to excessive levels of UV radiation, and one 
of the main mechanisms by which this UV radiation induces its oncogenic effect is 
through the generation of ROS.  These excessive ROS can then damage a number of 
cellular constituents, and seem especially harmful in that they can induce a state of 
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Figure 1.5 Diagram of the p16 structure. Flanked by flexible tails at the N and C 
termini, each ankyrin repeat exhibits a helix turn helix structure. The ankyrin repeats are 
designated as 1, 2, 3, and 4. The four ankyrin repeats are connected by three loops in β-
hairpin turn structure.  The individual ankyrin repeat is formed from a helix (red) loop 






dissertation demonstrates a novel functional link between the genetic melanoma 
predispositionary state of p16INK4A compromise and the environmental melanomagenic 
factor of excessive generation of intracellular oxidative stress.  Specifically, this work 
describes a novel, potentially tumor-suppressive role of p16INK4A in the regulation of 
intracellular oxidative stress that is independent of its canonical tumor-suppressive role of 
a cell-cycle regulator.  We report that this p16INK4A-mediated regulation of oxidative 
stress is common to several cell types, but the higher constitutive levels of ROS we 
observed in melanocytes may indicate why genetic compromise of p16INK4A predisposes 
individuals to melanoma more often than other cancers.  
Approximately 25-50% of familial melanoma kindreds and 10% of individuals 
with multiple primary melanomas show germline mutations in the CDKN2A locus (Soufir 
et al. 1998). Somatic alterations in CDKN2A have been reported in 30-70% of sporadic 
melanomas (Bartkova et al. 1996,Walker et al. 1998).  Because this single locus codes for 
two separate proteins and mutational events can cause loss of function for either or both 
of these proteins, it can be difficult to assess the individual roles of either protein in 
promoting oncogenesis.  Sporadic tumors have shown inactivation of p16INK4A and ARF 
through mutation (Pollock et al. 1996), promoter methylation (Merlo et al. 1995) or 
deletion (Cairns et al. 1995).    Melanoma samples have exhibited point mutations in the 
p16INK4A-specific exon 1α, and sequences shared by both p16INK4A and ARF, but not in 
the ARF-specific exon 1β.  Also, most mutations that do occur in the shared sequences do 
not affect the function of ARF (Hewitt et al. 2002).  Additionally, the CpG island that is 
methylation-silenced is in the p16INK4A promoter (Arap et al. 1997).  It thus appears that 
the more important tumor suppressor protein at the CDKN2A locus is p16INK4A. 
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Given my novel discovery that p16INK4A regulates intracellular oxidative stress 
independently of the Rb pathway and the Rb-mediated cell cycle regulation, I 
hypothesized that we may be able to functionally uncouple these two roles. Using 
mutagenic PCR, a panel of p16INK4A proteins harboring specific point mutations observed 
in familial melanoma was constructed. A lentiviral expression system was used to 
express these mutant proteins in a murine fibroblast line nullizygous for p16INK4A (Figure 
1.6).  Mutant proteins were classified according to their ability to restore cell cycle and/or 
oxidative stress regulation when compared to the re-expression of wild-type p16 
expressed in these same p16INK4A-deficient cells.  Interestingly, several mutants showed a 
restoration of one, but not both, functions.  Several mutants also showed an ability to 
functionally restore both oxidative and cell cycle regulation. It has been reported that the 
third ankyrin repeat is the region of p16INK4A that makes the most interactions with CDK 
4/6 (Byeon et al. 1998, Mahajan et al. 2007, Russo et al. 1998), but several mutations 
lie in other regions of p16INK4A. Interestingly, most mutations impairing oxidative but not 
cell-cycle function (A36P, A57V, P114S), or those not impairing either function (G35A, 
G35V, R24P), lie outside this repeat.  Taken together, this work describes a novel 
function of the cell cycle regulator p16INK4A in regulating intracellular oxidative stress.  
We also demonstrate that these two putative tumor suppressor functions can be 
uncoupled in a subset of familial melanoma-associated point mutants and that these 
































Figure 1.6 Schematic detailing mutant construction and analysis. Overlap PCR using 
mutagenic primers were used to construct a panel of 13 familial melanoma-associated 
p16INK4A point-mutants that spanned the coding region and have exhibited a range of 
CDK4/6 binding in previous literature.  Constructs where expressed in p16INK4A deficient 
murine fibroblasts and analyzed for their capacity to correctly localize to the nucleus, 
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p16INK4A -dependent upregulation of antioxidant enzymes is 
 secondary to modulation of ROS      
We considered several mechanisms by which p16INK4A loss may elevate cellular 
oxidative stress. First, we asked whether increased ROS in p16INK4A -depleted cells 
resulted directly from dysregulation of intracellular antioxidant enzymes. We initially 




-treated melanocytes, and 
found that mRNA levels of the stress protein heme oxygenase-1 (HO-1) were 
significantly increased 3 h after treatment (Supplementary Figure S2.5). On the other 
hand, expression of additional antioxidant enzymes including superoxide dismutase 1, 





-treated cells (although there was an increased trend for thioredoxin and 
peroxiredoxin 1) (Supplementary Figure S2.5). HO-1 has been shown to be a critical 
oxidant stress- inducible antioxidant defense mechanism in fibroblasts (Vile et al. 1994), 
and also appears to be the predominant antioxidant enzyme modulated by oxidative stress 
in melanocytes, consistent with a previous report (Marrot et al. 2008). 
Similarly, in the context of increased intracellular oxidative stress induced by 
p16INK4A knockdown, expression of HO-1 was significantly increased while that of 
thioredoxin and peroxiredoxin 1 was not (Supplementary Figure S2.6a). The effect of 
p16INK4A depletion on HO-1 expression, however, was secondary to increased ROS as 
addition of NAC effectively prevented this increase in HO-1 expression (Supplementary 
Figure S2.6a). These results were recapitulated at the protein level, as p16INK4A 
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knockdown resulted in increased HO-1 protein levels which were attenuated by addition 
of NAC (Supplementary Figure S2.6b). Thus HO-1 is the major antioxidant enzyme 
upregulated in melanocytes by oxidative stress, and its upregulation in p16INK4A -depleted 
cells appears to be secondary to increased ROS following p16INK4A knockdown since the 
antioxidant NAC blocks increased HO-1 expression. 
Oxidative dysregulation in p16-deficient cells is independent of  
cell cycle regulation  
In our published study, we considered the possibility that the observed suppressive 
effect of p16INK4A on ROS levels was related to its role in cell cycle regulation.  p16INK4A 
is an established negative regulator of the cell cycle, and it has been reported that cells 
with p16INK4A mutations exhibit faster proliferation rates and decreased fraction of cells 
in the G1 phase compared to cells with wild-type p16INK4A (Serrano et al. 1996). It is also 
known that increased proliferation is associated with increased mitochondrial respiration 
and in turn increased ROS leakage from the mitochondrial chain into the cytoplasm 
(Halliwell and Gutteridge 1990). Thus dysregulation of intracellular ROS in p16INK4A -
deficient cells could be secondary to increased proliferation resulting from loss of 
p16INK4A regulatory control of the cell cycle. Indeed, skin from p16INK4A -null mice 
showed a significant increase in proliferating (BrdU-positive) cells in the epidermis 
compared to that from wild-type mice (Supplementary Figure S2.7). Similarly, fibroblast 
lines from p16INK4A -null mice displayed a much larger population of proliferating cells 
than lines from wild-type mice, as reflected by a greater fraction of cells in the G2M 
phase with a minority of cells in the G1 phase (Supplementary Figure S2.8a). We again 
found elevated ROS levels in p16INK4A -deficient fibroblasts compared to wild-type cells 
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(Supplementary Figure S2.8b). Increased ROS levels in p16INK4A -deficient cells 
correlated with an increased fraction of cells staining for 8-OG (Supplementary Figure 
S2.9). 
To determine whether increased ROS associated with p16INK4A loss was due to 
increased proliferation, fibroblast lines from both p16INK4A -deficient and wild-type mice 
were serum-starved to synchronize both cell types with respect to cell cycle phase. 
Following serum starvation, the majority of p16INK4A -deficient cells were in the G1 
phase (Supplementary Figure S2.8a), resembling the cell cycle profile of wild-type cells. 
When cell lysates obtained from serum-starved cells were analyzed for intracellular ROS, 
we again found increased ROS levels in p16INK4A -deficient compared to wild-type cells 
despite their similar cell cycle profiles (Supplementary Figure S2.8b). Likewise, despite 
comparable cell cycle profiles, we also found an increased proportion of 8-OG positive 
cells in p16INK4A -deficient compared to wild-type cell lines (Supplementary Figure S2.9). 
Taken together, these data suggest that the dysregulated oxidative stress and resulting 
oxidative damage observed in p16INK4A -deficient cells is independent of p16INK4A -
regulated cell-cycle control. 
Supplementary Methods 
qRT-PCR  
RNA was harvested from cells using the RNeasy kit (Qiagen, Valencia, CA) as 
per the manufacturer’s instructions. Approximately 0.5 µg total RNA was reverse-
transcribed using SuperScript II Reverse Transcriptase (Invitrogen), and equal volumes 
of cDNA (1 µl of each 20 µl reaction) were subjected to PCR using primers specific for 
p16 (5’-CCCAACGCACCGAATAGTTAC-3’ and 5’ ACCACCAGCGTGTCCAGGAA-
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3’), HMOX1 (5’-CTGTGTCCCTCTCTCTGGAAA-3’ and 5’ 
TCCAGGCTCTGCTGCAGGAA-3’), SOD1 (5’-
TCACTTTAATCCTCTATCCAGAAA-3’ and 5’-CACCACAAGCCAAACGACTTC-
3’), SOD2 (5’-GGAGTTGCTGGAAGCCATCAA-3’ and 5’-
TCTCCCAGTTGATTACATTCCAA-3’), TRXRD1 (5’ 
GTGATGGAACAACTGTCAAATCA-3’ and 5’-ATAGCCTCCAAGGGAGCCAAA-
3’), PRDX1 (5’- TTTGGTATCAGACCCGAAGC-3’ and 5’- 
TCCCCATGTTTGTCAGTGAA-3’), or GAPDH (5’-CCCTCAACGACCACTTTGTC 
3’ and 5’-GGGTCTACATGGCAACTGTG-3’) for up to 40 cycles (95 °C for 10 s, 59 °C 
for 10 s and 72 °C for 20 s). The SyBR Advantage qPCR Premix Kit (Clontech, 
Mountain View, CA) was used according to the manufacturer’s instructions, and samples 
were run using a CFD-3240 Chromo4 detector (MJ Research, Waltham, MA) equipped 
with Opticon Monitor software (Promega Corporation, Madison, WI) for data 
acquisition, monitoring, and analysis. 
Cell cycle analysis 
Mouse fibroblasts at 40-50% confluency were cultured in 6-well plates with high 
glucose DMEM either unsupplemented (serum-starved) or supplemented with 10% FBS. 
After 72 h, cells harvested by trypsinization were washed with cold PBS, resuspended in 
500 µl of 70% ethanol, and then stored overnight at 4 °C. After washing in PBS, cells 
were resuspended in PBS containing 50 µg/ml propidium iodide (Sigma) and then 
analyzed on a FACSort using ModFit LT version 3.1 software (Verity Software House, 





Data from experimental groups were subjected to standard one- and two-sample t 
tests. P values < .05 were considered statistically significant. 
Proliferation in vivo 
Neonatal mice were injected i.p. with 5-bromo-2' deoxyuridine (BrdU, 50 mg/kg, 
Sigma), then 2 h later dorsal skin was excised and proliferating cells were detected by 
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Supplementary Figure S2.1  Generation of intracellular ROS and oxidative DNA 
damage in melanocytes treated with H2O2.  (a) Melanocytes were either untreated or 
treated with 5 mM NAC and/or 0.05 mM H2O2.  After 5 h, ROS levels were measured by 
DCFDA assay, and values normalized to control conditions which were set at 1.  Error 
bars indicate SEM from three independent experiments.  *P=.01 (two-sample t test).  (b) 
Cells were either untreated or treated with 5 mM NAC and/or 0-2 mM H2O2.  After 48 h, 
cells were fixed and immobilized for 8-OG staining.  Error bars indicate SEM of percent 
8-OG positive cells assessed under each condition in three independent experiments.  

















Supplementary Figure S2.2  p16INK4A depletion in multiple human cell types.  (a) 
Melanocytes, (b) keratinocytes,  and (c) fibroblasts independently isolated from four 
seperate donors were transfected either with control scrambled (Scr) or p16-specific 


















Supplementary Figure S2.3  Oxidative dysregulation in p16INK4A -depleted melanocytes 
not due to alterations in cell-cycle phase.  (a) Human melanocytes independently isolated 
from four separate donors were transfected with either control scrambled (Scr) or 
p16INK4A -specific siRNA, and 48 h later cell lysates were blotted for p16 or Actin.  (b) 
Cell cycle analysis was performed on siRNA-transfected cells in (a), with percentages of 
cells in each phase (G1, S, G2M) indicated.  Error bars indicate SEM from four separate 
donors.  ns, not significant (paired two-sample t tests).  (c) ROS levels were determined 
by DCFDA assay in siRNA-transfected cells in (a).  Error bars indicate SEM from four 
separate donors.  *P<.001 (repeated measures analysis of variance, ANOVA).  (d) 8-OG 
staining was performed in siRNA-transfected cells in (a) after an additional 48 h.  Error 































Supplementary Figure S2.4 Upregulation of the predominant antioxidant enzyme HO-1 









RNA was isolated 3 and 5 h later for qRT-PCR analysis of expression of HO-1, 
superoxide dismutase 1 (SOD1), superoxide dismutase 2 (SOD2), thioredoxin (TRX), 
and peroxiredoxin 1 (PRX) as indicated. Error bars indicate SEM from three independent 









Supplementary Figure S2.5 Upregulation of the predominant antioxidant enzyme HO-1 
occurs in response to p16 knockdown, and in p16INK4A -deficient cells is blocked by 
NAC.  (a) Melanocytes were transfected with siRNA against control scrambled sequence 
(Scr) or p16 in the absence or presence of NAC, then 48 h later RNA was isolated and 
qRT-PCR was performed for HO-1, thioredoxin (TRX), and peroxiredoxin 1 (PRX) as 
indicated. Expression levels for each gene were normalized to GAPDH, and under 
control conditions value was set at 1. Error bars indicate SEM from three independent 
experiments. *P=.05, **P=.09, ***P=.19 (two-sample t tests).  (b) Melanocytes were 
transfected with siRNA against control scrambled sequence (Scr) or p16INK4A in the 
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6 p16INK4A -deficient cells show increased proliferation 
-type and p16-null mice following injection of BrdU, 













Supplementary Figure S2.7 Oxidative dysregulation in p16INK4A -deficient cells is 
independent of p16INK4A -regulated cell-cycle control. B. Two fibroblast lines derived 
from both wild-type and p16-null mice were cultured in the presence (control, left panel) 
or absence (serum-starved, right panel) of FBS for 72 h. Cell cycle analysis was then 
performed, and percentages of cells in each phase are indicated. Error bars indicate SEM 
from five independent experiments. (a) Lysates from fibroblast lines under control (left 
panel) or serum-starved (right panel) conditions were subjected to DCFDA assay for 
ROS. Error bars indicate SEM from three independent experiments. *P<.001, **P<.001 
(repeated measures analysis of variance, ANOVA).  (b) Fibroblast lines under control 
(left panel) or serum-starved (right panel) conditions were stained for 8-OG. Error bars 














Supplementary Figure S2.8  Oxidative damage in p16INK4A -deficient cells is 
independent of p16INK4A -regulated cell-cycle control. Fibroblast lines under control (left 
panel) or serum-starved (right panel) conditions were stained for 8-OG. Error bars 

















FAMILIAL MELANOMA-ASSOCIATED MUTATIONS IN P16 













Familial melanoma is associated with point mutations in the cyclin-dependent 
kinase (CDK) inhibitor p16INK4A. We recently reported that p16INK4A regulates 
intracellular oxidative stress in a cell cycle-independent manner. Here, we constructed 12 
different familial melanoma-associated point mutants spanning the p16INK4A coding 
region and analyzed their capacity to regulate cell-cycle phase and suppress reactive 
oxygen species (ROS). Compared to wild-type p16INK4A which fully restored both 
functions in p16INK4A-deficient fibroblasts, various p16INK4A mutants differed in their 
capacity to normalize ROS and cell cycle profiles. While some mutations did not impair 
either function, others impaired both. Interestingly, several impaired cell-cycle (R24Q, 
R99P, V126D) or oxidative function (A36P, A57V, P114S) selectively, indicating that 
these two functions of p16INK4A can be uncoupled. Similar activities were confirmed with 
selected mutants in human melanoma cells. Many mutations impairing both cell-cycle 
and oxidative functions, or only cell cycle function, localize to the third ankyrin repeat of 
the p16INK4A molecule. Alternatively, most mutations impairing oxidative but not cell-
cycle function, or those not impairing either function, lie outside this region. These 
results demonstrate that particular familial melanoma-associated mutations in p16INK4A 
can selectively compromise these two independent tumor-suppressor functions, which 
may be mediated by distinct regions of the protein. 
The CDK4/6 inhibitor p16INK4A is encoded by the chromosomal locus CDKN2A 
and altered in the majority of human tumors (Sharpless and DePinho 1999). Germ-line 




namely pancreatic carcinoma and melanoma, and are inherited in approximately 40% of 
melanoma-prone families (Goldstein et al. 2007).  In the presence of potentially 
oncogenic stress such as DNA damage, the canonical tumor-suppressor function of 
p16INK4A involves binding either to cyclin-dependent kinases 4 and/or 6 (CDK4/6) or 
preassembled CDK4/6-cyclin D complexes (Hirai et al. 1995, Serrano et al. 1993), 
inhibiting hyperphosphorylation of Retinoblastoma-associated pocket proteins and 
delaying cell cycle progression from the G1 to S phase (Alcorta et al. 1996, Lukas et al. 
1995). In this setting, p16INK4A may induce cellular senescence or allow time for DNA 
repair prior to cell division (Shapiro et al. 1998). Interestingly, several studies have 
demonstrated that many familial melanoma-associated p16INK4A mutants retain CDK4-
binding capacity in vitro (Becker et al. 2001, Hashemi et al. 2000, Kannengiesser et al. 
2009, McKenzie et al. 2010), suggesting that p16INK4A may mediate an additional 
important function(s) independent of cell-cycle regulation. 
Since penetrance of melanoma in p16INK4A mutant kindreds is highly associated 
with chronic exposure to ultraviolet radiation (Bishop et al. 2002), which produces 
reactive oxygen species (ROS) in the skin (Herrling et al. 2006), we recently investigated 
a possible role for p16INK4A in regulating intracellular oxidative stress. We found 
increased oxidative stress in multiple skin cell types when depleted of p16INK4A that was 
independent of cell-cycle regulation (Jenkins et al. 2011). Melanocytes demonstrated 
increased susceptibility to oxidative stress in the context of p16INK4A depletion compared 
to keratinocytes and fibroblasts (Jenkins et al. 2011). Melanocytes thus appear to be more 
dependent on p16INK4A for normal oxidative regulation than other cell types, which may 
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in part explain why inherited mutations in p16INK4A predispose to melanoma over other 
cancers. 
Given this newly identified role of p16INK4A in regulating intracellular oxidative 
stress, we investigated whether different familial melanoma-associated p16INK4A 
mutations can differentially modulate its cell cycle and oxidative regulatory functions. A 
panel of p16INK4A mutants was constructed and compared to wild-type p16INK4A in 
functional assays using p16-/-Arf+/+ cells. Interestingly, several mutations selectively 
compromised control of cell-cycle or oxidative stress, effectively uncoupling these two 
functions. Taken together, these data show that these two potential tumor-suppressor 
functions of p16INK4A can be independently disrupted by distinct familial melanoma-




Wild-type p16 suppresses ROS and cell cycle progression, and  
induces senescence in p16-/- Arf+/+ cells 
 
Our previous experiments (Jenkins et al. 2011) demonstrating sufficiency of 
p16INK4A  in mediating control of intracellular oxidative stress were performed in 
fibroblasts deficient in CDKN2A, which encodes both the p16INK4A and Alternative 
reading frame (Arf, p19) proteins (Sharpless and DePinho 1999). We began by 
confirming these results using cells that were selectively deficient in p16INK4A (i.e., wild-
type for Arf). Fibroblasts from wild-type mice were infected with control lentivirus 
expressing green fluorescent protein (GFP), while p16-/-Arf+/+ fibroblasts were separately 
infected with either lentivirus expressing p16INK4A and GFP or GFP alone. We had 
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previously optimized conditions for viral transduction to achieve 80-90% infection rates 
(as measured by GFP visualization using fluorescence microscopy) and expression of 
exogenous p16INK4A (by Western blotting) roughly equivalent to p16INK4A levels in wild-
type fibroblasts (72 h after lentiviral infection). Infection of p16INK4A -deficient cells with 
p16INK4A lentivirus resulted in p16INK4A levels comparable to that observed in wild-type 
cells (Figure 3.1a, bottom), and was associated with normalization of ROS while ROS 
levels were significantly higher in p16INK4A -deficient cells infected with GFP lentivirus 
(Figure 3.1a, top). These control (GFP) p16-/-Arf+/+ cells also exhibited a dysregulated 
cell cycle profile evidenced by marked decrease in the proportion of cells in G1 phase 
and increase in the proportion in G2/M phase (Figure 3.1b). Introduction of p16INK4A  
expression in p16-/-Arf+/+ cells normalized the cell cycle distribution, increasing the 
fraction of cells in G1 phase and decreasing the fraction in G2/M phase (Figure 3.1b). 
These results provide evidence that expression of p16INK4A is both necessary and 
sufficient in p16-/-Arf+/+ cells to mediate oxidative and cell-cycle regulation. 
Excessive ROS may lead to cellular senescence in some circumstances (Macleod 
2008).  Previous reports indicated in some experimental systems that p16INK4A expression 
was associated with both senescence and increased ROS (Takahashi et al. 2006), while in 
others increased p16INK4A expression was not associated with increased ROS (Macip et 
al. 2002). Thus, we examined whether reduced ROS associated with introduction of 
p16INK4A into p16-/-Arf+/+ cells was associated with cellular senescence. The p16-/-Arf+/+ 
fibroblasts were separately infected with either lentivirus expressing p16INK4A /GFP or 
GFP alone, and then assessed for β-galactosidase (β-gal) activity at pH 6.0 over a 7-day 




Figure 3.1. p16INK4A expression normalizes ROS and cell-cycle profile in p16-/-Arf+/+ 
cells. (a) Wild-type (WT) and p16INK4A-deficient fibroblasts were infected with either 
GFP (control) lentivirus or lentivirus expressing wild-type p16 as indicated. After 72 h, 
cell lysates were subjected to DCFDA assay for intracellular ROS (upper panel) and 
western blotting for p16, Arf, or actin (lower panel). Error bars indicate SEM from 
triplicate determinations. (b) After 72 h, cell cycle analysis was performed with 
percentages of cells in each phase (G1, S, G2M) indicated. Error bars indicate SEM from 
triplicate determinations. (c) p16INK4A-deficient fibroblasts were infected with either GFP 
(control) lentivirus or lentivirus expressing wild-type p16, then after the indicated time 
staining for β-gal was performed at pH 6.0. Average values were determined from three 





1995). We found that while no senescent cells were evident in cultures of p16-/-Arf+/+ 
fibroblasts infected with control GFP lentivirus, cells infected with p16INK4A lentivirus 
were increasingly positive for senescence-associated β-gal staining over 7 days 
(Figure 3.1c, Figure 3.2). Thus although the relationship between p16INK4A expression 
and ROS appears subject to experimental context (Vurusaner et al. 2012), in our system 
restoring p16INK4A expression correlates with reduced ROS and increased G1 arrest and 
senescence. 
Functional activities of familial melanoma-associated p16INK4A mutants 
 
To investigate the potential functional consequences of particular mutations in 
p16INK4A that have been identified in human melanoma kindreds (Becker et al. 2001, 
Hashemi et al. 2000, Kannengiesser et al. 2009, McKenzie et al. 2010), we prepared 
lentiviral constructs encoding 12 point mutants that span the length of the p16INK4A coding 
region (Table 3.1). While nine of the mutations would be predicted to affect only the 
p16INK4A and not Arf coding sequences (R24P, R24Q, G35A, G35V, A36P, A57V, L97R, 
R99P, V126D), the remaining three mutations would be predicted to affect both p16INK4A 
and Arf (P81T, R87W, P114S). Each mutant was separately expressed in p16-/-Arf+/+ 
fibroblasts, and levels of ROS and cell cycle distribution were determined and compared 
to that found in cells expressing either GFP or wild-type p16INK4A. We found that several 
p16INK4A mutants exhibited an impaired capacity to regulate both oxidative stress and the 
cell cycle. For example, ROS levels and cell cycle distribution remained dysregulated in 
cells expressing the P81T mutant compared to wild-type p16INK4A (Figure 3.3a). A similar 








Figure 3.2 p16INK4A expression induces senescence.  p16INK4A-deficient fibroblasts were 
infected with either (a) GFP (control) lentivirus or (b) lentivirus expressing p16INK4A, 
then after 7d staining for β-gal was performed at pH 6.0. Representative staining (arrows 




















Table 3.1   List of primers used to construct either wild-type p16INK4A or the 12 familial 
melanoma-associated point mutations of interest.  Underlined nucleotides in the wild-
typer primer sequences indicate PstI and XhoI sites introduced by PCR for further 
subcloning.  Lower case bold letters in other primer sequences represent bases used to 



















Primer 1 Primer 2 




































L97R T290G GCgGCACCGGGCCGGGGCGCGGCTGG CCAGCCGCGCCCCGG
CCCGGTGCcGC 
R99P G296C GCACCcGGCCGGGGCGCGGCTGG CCAGCCGCGCCCCGG
CCgGGTGC 







All sequences are 5’ to 3’.  Lower case bold letters in sequences indicate point mutations 
introduced. 














Figure 3.3 Functional activities of familial melanoma-associated p16INK4A mutants. 
p16INK4A-deficient fibroblasts were infected with the indicated lentiviral constructs 
expressing GFP, wild-type p16INK4A, or (a) mutants P81T or A57V, (b) mutants A36P or 
L97R, (c) mutants R87W or P114S, or (d) mutants G35A or R99P. Cell lysates were 
prepared for detection of ROS and p16 protein levels (upper panels in each). Cell cycle 
analysis was performed with percentages of cells in each phase (G1, S, G2M) indicated 








Thus three of the 12 mutants could be categorized as “double loss of function” (Figure 
3.4).  Interestingly, several p16INK4A mutants largely restored regulation of both oxidative 
stress and cell cycle distribution. For example, expression of the G35A mutant resulted in 
ROS levels and cell cycle distribution comparable to that of cells expressing wild-type 
p16INK4A (Figure 3.3d). A similar phenotype was observed for the R24P (Figure 3.5) and 
G35V (Figure 3.6) mutants. The identification of these three mutants (none of which 
affect Arf) that largely retain both oxidative and cell cycle regulatory functions (Figure 
3.4) suggests that some mutations in p16INK4A may affect melanoma predisposition by 
disrupting other (tumor suppressor-related yet undefined) functional activities. 
Uncoupling of cell cycle and oxidative regulatory functions 
For the remaining six p16INK4A mutants, we found that the oxidative or cell cycle 
regulatory activity was selectively compromised. For example, the A57V mutant 
normalized cell-cycle distribution comparable to wild-type p16INK4A, but did not correct 
elevated ROS levels (Figure 3.2a). Similarly, the A36P (Figure 3.3b) and P114S mutants 
(Figure 3.3c) demonstrated selective loss of oxidative compared to cell cycle regulation. 
The inverse result was observed with the R99P mutant, which effectively suppressed 
ROS levels but did not restore cell-cycle distribution (Figure 3.3d, Figure 3.7). Similarly, 
selective loss of cell cycle compared to oxidative regulatory function was observed in the 
V126D (Figure 3.5) and R24Q (Figure 3.7) mutants. Thus the identification of these six 
mutants in which the oxidative and cell cycle regulatory functions are relatively 
uncoupled (Figure 3.4) supports our previous contention that p16INK4A regulates oxidative 











Figure 3.4 Summary of functional analyses of familial melanoma-associated p16INK4A 
mutants.  Percent restoration (relative to wild-type p16INK4A, set at 100%) of cell cycle or 
oxidative regulatory function is shown after each construct was expressed in p16INK4A -












Figure 3.5 Functional activities of familial melanoma-associated p16INK4A mutants R24P 
and V126D. (a) p16INK4A -deficient fibroblasts were infected with the indicated lentiviral 
constructs, and cell lysates were used for detection of ROS and p16INK4A protein levels. 
Error bars indicate SEM from triplicate determinations. ns, not significant. (b) Cell cycle 
analysis was performed with percentages of cells in each phase (G1, S, G2M) indicated. 







Figure 3.6 Functional activities of familial melanoma-associated p16 mutants G35A 
and G35V. (a) p16INK4A -deficient fibroblasts were infected with the indicated lentiviral 
constructs, and cell lysates were used for detection of ROS and p16INK4A protein levels. 
Error bars indicate SEM from triplicate determinations. ns, not significant. (b) Cell cycle 
analysis was performed with percentages of cells in each phase (G1, S, G2M) indicated. 







Figure 3.7 Functional activities of familial melanoma-associated p16INK4A mutants R24Q 
and R99P. (a) p16INK4A -deficient fibroblasts were infected with the indicated lentiviral 
constructs, and cell lysates were used for detection of ROS and p16INK4A protein levels. 
Error bars indicate SEM from triplicate determinations. (b) Cell cycle analysis was 
performed with percentages of cells in each phase (G1, S, G2M) indicated. Error bars 





p16INK4A mutants with altered functional activities retain  
appropriate subcellular localization 
It is generally thought that p16INK4A localizes to the nucleus to exert its CDK-
inhibitory function (Bartkova et al., 1996; Lukas et al., 1995), although there are reports 
of p16INK4A revealing both nuclear and (sparse) cytoplasmic localization (Geradts et al., 
2000; McKenzie et al., 2010). Others have found that exogenous over-expression of 
p16INK4A can lead to protein aggregation and unfolding in the cytoplasm, resulting in loss 
of function (Tevelev et al., 1996). It has also been suggested that cytoplasmic localization 
of p16INK4A may represent a specific mechanism of its inactivation in tumors (Evangelou 
et al., 2004). Given these considerations, it was important to demonstrate that alterations 
in functional activities seen here with some p16INK4A mutants were not due to 
mislocalization of the protein. Therefore, we assessed subcellular localization of each 
p16INK4A mutant in p16-/-Arf+/+ fibroblasts by immunofluorescence. First, we confirmed 
that wild-type p16INK4A was strongly nuclear, colocalizing with DAPI-staining nuclei, and 
no cytosolic expression was detected (Figure 3.8). Analysis of the 12 p16INK4A point 
mutants consistently showed similar nuclear localization (Figure 3.8), providing strong 
evidence that their various altered functional activities could not be attributed to 
mislocalization of p16INK4A.  
Analysis of p16INK4A -regulatory functions in human melanoma cells 
Next, we examined a subset of these mutants in human melanoma cells – perhaps 
a more relevant model for analyzing p16 mutations associated with familial melanoma. 






Figure 3.8 Nuclear localization of p16INK4A mutants. p16-/-Arf+/+ fibroblasts were infected 
with the indicated lentiviral constructs. Cells were fixed, permeabilized and stained for 






either GFP, wild-type p16INK4A, or a selected p16INK4A mutant. As above, we optimized 
expression of individual mutants to be comparable to expression levels of wild-type 
p16INK4A by Western blotting (Figure 3.9a, b). As we observed in p16-/-Arf+/+ mouse 
fibroblasts (Figure 3.1), expression of wild-type p16INK4A (compared to GFP control) was 
associated both with suppression of ROS levels (Figure 3.9c, d) and shift of the cell cycle 
distribution (Figure 3.9e,f). Mirroring the phenotypes seen above (Figure 3.2c, d), the 
R99P mutant retained oxidative but not cell cycle function while the P114S mutant 
exhibited the reciprocal phenotype (Figure 3.9c, e) in WM793 cells. Compared to wild-
type p16INK4A, the R24Q mutant was unable to restore significant oxidative (Figure 3.9d) 
or cell cycle function (Figure 3.9f) consistent with our earlier findings (Figure 3.7). 
Finally, as seen above (Figure 3.6), the G35V mutant retained cell cycle function 
comparable to wild type p16INK4A (Figure 3.9f), but exhibited limited capacity for 
reducing ROS (Figure 3.9d). Importantly, the differential capacity of three p16 mutants 
(R99P, P114S, G35V) to regulate oxidative versus cell cycle regulatory functions was 
recapitulated in human melanoma cells. 
Structure-function relationships among p16INK4A mutants 
In order to gain insight into the different functional activities associated with 
particular p16INK4A mutants, we examined their relative localization based on published 
structures of the molecule (Byeon et al., 1998; Russo et al., 1998). p16INK4A consists 
mainly of four ankyrin repeats, a conserved motif of approximately 30 amino acids, 
which is involved in various protein-protein interactions (Li et al., 2006). These repeats 
create a pair of antiparallel helices forming a stem and a β-hairpin forming the base of an 






Figure 3.9 Uncoupling of oxidative and cell cycle regulatory functions by p16INK4A 
mutants in WM793 human melanoma cells. (a, b) WM793 cells were infected with the 
indicated lentiviral constructs, and cell lysates were collected either 16 h or 48 h post-
infection for western blotting. (c, d) ROS levels were determined in cell lysates 16 h 
postinfection with the indicated lentivirus. Error bars indicate SEM from triplicate 
determinations. ns, not significant. (e, f) Cell cycle analysis was performed 48 h post-
infection with percentages of cells in each phase (G1, S, G2M) indicated. Error bars 





have implicated all four ankyrin repeats as important for CDK4/6-binding and cell cycle 
inhibition, others indicate that the third ankyrin repeat (residues 81-113) as well as the β-
hairpin loop within the second ankyrin repeat (residues 52-54) are the most critical 
regions for mediating these functions (Byeon et al., 1998, Mahajan et al., 2007, Russo et 
al., 1998). Consistent with this notion, several residues that we found to be important for 
both cell-cycle and oxidative regulation (P81, R87, L97), or only cell-cycle regulation 
(R99), reside in the third ankyrin repeat (Figure 3.10). By contrast, most residues 
important for oxidative but not cell-cycle regulation (A36, A57, P114), or those not 
important for either function (G35, R24), are not found within the third ankyrin repeat or 
the β-hairpin loop of the second ankyrin repeat (Figure 3.10). 
We recently described a novel role for p16INK4A in suppressing intracellular 
oxidative stress, functioning independently of cell cycle and its control of the Rb pathway 
(Jenkins et al., 2011). These two regulatory functions are likely to be complementary in 
preventing potentially oncogenic oxidative DNA lesions by decreasing their formation 
(reduction of ROS) and propagation (induction of cell cycle arrest to allow DNA repair). 
In this study we examined separately the cell cycle and oxidative stress regulatory 
capacities of a panel of familial melanoma-associated p16INK4A point mutations spanning 
the p16INK4A coding region. These mutants varied in their abilities to restore these two 
regulatory functions when expressed in p16INK4A –deficient fibroblasts, and could be 
grouped into distinct categories: those that restored both functions (R24P, G35A, G35V), 







Figure 3.10 Localization of critical residues on p16INK4A. Residues important for 
regulation of (a) cell-cycle (black circles) and (b) oxidative stress (gray circles) are 
highlighted on the p16INK4A backbone structure which exhibits 4 ankyrin repeats 
(numbered 1-4). Note that G35 is not depicted since neither G35A nor G35V 







regulation, or failed to restore either function (R87W, L97R, P81T). These findings are 
further evidence that p16INK4A is sufficient to regulate intracellular oxidative stress 
independently of its canonical role in cell-cycle regulation, and that these roles can be 
individually compromised by particular familial melanoma-associated mutations. 
Historically, the cell cycle regulatory function of some of these and other 
p16INK4A mutants found in patients was assessed by measuring CDK4-binding – a 
reasonable surrogate since p16INK4A binding to CDK4/6 is the critical step leading to 
reduction in Rb phosphorylation and inhibition of the G1/S transition of the cell cycle 
(Alcorta et al., 1996, Lukas et al., 1995). The two primary assays employed were based 
on yeast two-hybrid (Yang et al., 1995) and immunoprecipitation (Becker et al., 2001; 
Hashemi et al., 2000; Kannengiesser et al., 2009) approaches. These assays, however, 
have been problematic for two reasons. First, several mutants were found to retain the 
capacity to bind CDK4, yet were greatly reduced in their capacity to regulate the cell 
cycle (Becker et al., 2001, Koh et al., 1995). These discrepancies could reflect the 
additional known capacity of p16INK4A to bind CDK6 and intact CDK4/6-cyclinD 
complexes in addition to CDK4 (Hirai et al., 1995, Serrano et al., 1993), neither of which 
was measured in these studies. Differences in functional assays may also relate to the 
potential ability of p16 to bind and inhibit CDK7, a kinase subunit of the TFIIH 
transcription factor (Serizawa 1998). Given the requirement of TFIIH-mediated 
phosphorylation of RNA polymerase II for transcription, p16INK4A may induce cell cycle 
arrest independently of CDK4/6 by binding to CDK7 (Nishiwaki et al., 2000). In addition 
to lack of correlation between CDK4- binding and cell-cycle inhibitory functions found 
in some cases, other studies have reported differences in CDK4-binding activity for the 
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same p16 mutant. For example, the reported CDK4-binding activity of the relatively 
common G101W mutant ranged from 5 to 73% of wildtype, based on yeast two-hybrid 
(Reymond and Brent 1995, Yang et al., 1995) and immunoprecipitation assays (Becker et 
al., 2001, Parry and Peters 1996, Ranade et al., 1995, Walker et al., 1995). A mammalian 
two-hybrid assay has also been used to measure interactions between p16INK4A mutants 
and CDK4 in human osteosarcoma (Saos-2) cells (McKenzie et al., 2010). While this 
experimental system has the advantage of retaining a more appropriate intracellular 
environment allowing for posttranslational modifications, there could be important 
differences between these tumor cells and melanocytes or melanoma cells. Rather than 
developing our own assay based on CDK4-, CDK6- or CDK4/6-cyclin D binding, we 
wanted to avoid these pitfalls and directly measure cell-cycle regulatory activity; thus we 
determined cell-cycle distribution by flow cytometry (which was highly reproducible) as 
a readout of the cell-cycle regulatory function of these p16INK4A mutants. 
Several previous studies have characterized the cell cycle regulatory capacity of 
different familial melanoma-associated p16INK4A point mutants. Overall, a wide range of 
phenotypes were reported among different mutants, as well as conflicting results 
concerning the same mutants. The basis for some of the discrepancies may lie in the 
different assays and cell types used for assessing cell cycle function, which included 
ability to induce phase arrest (Becker et al., 2001, Becker et al., 2005, Koh et al., 1995, 
McKenzie et al., 2010, Miller et al., 2011), limit cell numbers in culture (Jones et al., 
2007, Kannengiesser et al., 2009), reduce proliferation by Ki67/BrdU staining (Jones et 
al., 2007, McKenzie et al., 2010), and reduce colony formation (Becker et al., 2005, 
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Jones et al., 2007) in fibroblasts, osteosarcoma, and melanoma cells. For the mutants 
studied here, however, our results largely agreed with what has been reported in the 
literature. For example, our observations that cell cycle function was retained (R24P, 
G35A, G35V) or only partially diminished (A36P, A57V, P114S) in these particular 
mutants is consistent with prior reports (Jones et al., 2007, Kannengiesser et al., 2009, 
McKenzie et al., 2010). Similarly, our findings that cell cycle function was largely 
diminished (V126D) or completely absent (R99P, R87W, L97R) in other mutants is 
consistent with previous studies (Becker et al., 2001, Kannengiesser et al., 2009; 
McKenzie et al., 2010, Miller et al., 2011). On the other hand, the lack of cell cycle 
regulatory function that we observed for mutants R24Q and P81T was not consistent with 
earlier studies in which the R24Q (Kannengiesser et al., 2009) and P81T (McKenzie et 
al., 2010) mutants were found to be comparable to wild-type p16INK4A. For the R24Q 
mutant, we confirmed lack of cell cycle function in WM793 human melanoma cells 
(Figure 3.9f). As suggested above, one explanation for these discrepancies in addition to 
the different assays is that different cell types were employed. The capacity of some 
mutants to regulate cell cycle may be unmasked in particular cellular contexts depending 
on the different interactions of p16INK4A (i.e. with various CDKs) that could be affected. 
In addition, some cell lines may be less susceptible to regulation by exogenous p16INK4A 
due to the presence of background mutations, or loss of the entire CDKN2A locus with 
corresponding lack of dependency on p16INK4A or ARF. By testing the regulatory 
functions of these different mutants in primary fibroblasts, we gain insight into their 
behavior as potential tumor suppressors in an otherwise wild-type genetic background. 
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It has been reported that the third ankyrin repeat of p16INK4A (residues 81-113) 
and a β-hairpin loop in the second ankyrin repeat (residues 52-54) are the most important 
regions for CDK4- binding, as a 20-residue synthetic peptide (consisting of amino acids 
84-103) was able to bind CDK4 (Fahraeus et al., 1996). Subsequent studies reported that 
numerous residues along the entire p16INK4A molecule are important in some capacity for 
CDK4-binding, but still identified residues very near or in the third ankyrin repeat as 
being the most significant (Byeon et al., 1998; Li et al., 1999; Mahajan et al., 2007). Our 
results further confirm the importance of this region in p16INK4A for cell cycle regulation, 
as the R99P mutant which demonstrates the most dramatic loss of cell cycle function 
while retaining oxidative function (Figure 3.4) is located in the third ankyrin repeat 
(Figure 3.10). This region forms both an extensive hydrogen-bond network at the 
interface of CDK4/6 (involving residues 74, 84, and 87 of p16) and a mostly hydrophobic 
structural core that interacts with the other internal helices that may help stabilize the 
protein (Russo et al., 1998). Perhaps several mutations in this region upset either the 
hydrogen bond network of the binding interface or these internal stabilizing helices, as 
most mutants that fail to restore both cell cycle and oxidative regulatory function (P81T, 
R87W, L97R) are located here (Figure 3.10). Consistent with this notion, the mutants we 
found that fail to impair either function (R24P, G35A, G35V), or that selectively 
impaired oxidative regulation (A36P, A57V, P114S), are located outside of this region 
and the β-hairpin loop in the second ankyrin repeat known to form hydrogen-bond 
backbone contacts with CDK4/6 (Russo et al., 1998). These residues may be involved in 
direct or indirect interactions with yet uncharacterized binding partners of p16INK4A, or 
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mutations of these residues could alter the secondary structure of the p16INK4A molecule 
that precludes interactions required for oxidative regulatory function. The effects of 
particular mutations studies here (if any) on p16INK4A structure are difficult to predict 
without analysis of crystal structures of the mutant p16INK4A molecules. 
The identification of several familial melanoma-associated mutants that largely 
retain both oxidative and cell cycle regulatory function (Figure 3.4) suggests that some 
mutations in p16INK4A may affect melanoma predisposition by disrupting some other yet-
to-be defined tumor suppressor function. There is precedent for other well-studied tumor 
suppressor genes that appears to regulate ROS independently of their canonical functions 
(Vurusaner et al., 2012). For example, p53 which is involved in multiple cellular 
processes, including apoptosis, cell cycle arrest and senescence (Lane 1992), is a 
regulator of ROS. Several p53-target genes include redox-active proteins and ROS-
generating enzymes (Macip et al., 2003, Polyak et al., 1997). In addition, many post-
translational modifications of p53 generate ROS leading to activation of p38 mitogen-
activated protein kinase (Bragado et al., 2007). Another example is the CDK inhibitor 
p21 that promotes cell cycle arrest and DNA repair (Li et al., 1994) that was reported to 
regulate oxidative stress through the Nrf2 pathway.  p21 increases stability of Nrf2 by 
competing for Keap1 binding, which protects Nrf2 from ubiquination and subsequent 
degradation, allowing increased Nrf2-mediated transactivation of several antioxidant 
enzymes through binding to antioxidant response elements in their promoters (Chen et 
al., 2009). Finally, the breast cancer susceptibility genes BRCA1 and BRCA2 that are 
implicated in regulating cell cycle progression and maintaining genomic integrity (Rosen 
et al., 2003) also appear to be involved in regulating oxidative stress. BRCA1 upregulates 
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multiple antioxidant genes, including glutathione S-transferases and oxidoreductases 
(Bae et al., 2004). In addition, both BRCA1 and BRCA2 are required for the repair of the 
oxidative DNA lesion 8-oxoguanine (Le Page et al., 2000). The elucidation of non-
canonical roles of p16INK4A as well as these other tumor suppressors in the regulation of 
cellular oxidative stress may signal the development of a new paradigm in which tumor-
suppressor proteins employ multiple mechanisms that may be disabled in cancer, or in 
patients with cancer predisposition syndromes. 
Materials and Methods 
Cell culture 
Murine fibroblasts were isolated from newborn wild-type (FVB) and background-
matched p16-/- Arf+/+ (#01XE4, FVB.129-Cdkn2atm2.1Rdp) homozygous mice (Kamijo et 
al., 1997), both obtained from the National Cancer Institute (Rockville, MD, USA), as we 
have previously described (Jenkins et al., 2011). These procedures were approved by the 
University of Utah  IACUC. Early passage cells (approximately two weeks after 
isolation) were aliquoted and stored at -80 oC. For each set of experiments, fresh cells 
were thawed and used over a 2-3 week period. WM793 melanoma cells were originally 
obtained from Meenhard Herlyn (Wistar Institute, Philadelphia, PA, USA). 
Western blotting 
Specific proteins were detected in cell lysates by Western blotting as previously 
described (Jenkins et al., 2011). Primary antibodies were used against p16INK4A (1:1000, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-actin (1:10 000, A-3853, Sigma-
Aldrich, St. Louis, MO, USA), and ARF (1:1000, sc-22784, Santa Cruz Biotechnology). 
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Measurement of oxidative stress 
Endogenous ROS of protein equivalents (30 µg) were quantified using 2,7-
dichlorodihydrofluorescein diacetate (DCFDA, Life Technologies, Grand Island, NY, 
USA) as previously described (Jenkins et al., 2011). All experiments were performed in 
triplicate. 
p16INK4A -expressing lentiviruses 
The lentivirus expressing human wild-type p16INK4A is previously described 
(Jenkins et al., 2011). The p16INK4A point mutant constructs were generated by PCR-
based segment overlap as described previously (Raj et al., 2008), using human p16INK4A 
cDNA as a template and primers designed to create specific point mutations. Briefly, an 
initial PCR reaction was used to separately create the 5’ and 3’ fragments for each 
mutant. The 5’ fragment was constructed using wild-type p16INK4A sequence as “primer 
1” and mutant sequence as “primer 2”, and the 3’ fragment was constructed using wild-
type p16 sequence as “primer 2” and mutant sequence as “primer 1” (see Supplemental 
text, Table S1). A second PCR reaction was then used to anneal these individual 
segments, using equimolar amounts of the 5’ and 3’ fragments as template and primers 
corresponding to wild-type p16INK4A. The final PCR product was cloned into a modified 
pHIV-Zsgreen (Addgene #18121) lentiviral expression vector (Welm et al., 2008) and 
confirmed by DNA sequencing. Each lentiviral construct was validated for p16INK4A 
expression by transient transfection into HeLa cells followed by western blotting. Viruses 
were produced in HEK 293T/17 cells (ATCC, Manassas, VA, USA) co-transfected with 
5 µg lentiviral vector and 1.7 µg of each helper plasmid (pRSV-REV, pMDLg/pRRE and 
pVSVG, generously provided by Brian Welm, Huntsman Cancer Institute) and 30 µg of 
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polyethylenimine (pH 7.0, Sigma) in 1 mL of OptiMEM (Life Technologies). Viral 
particles were collected, purified, concentrated, titered, and stored as described 
previously (Jenkins et al., 2011). For cellular infection, 8 µg per mL polybrene (Sigma) 
was added. Assays for oxidative stress and cell cycle distribution in WM793 cells were 
performed 16 h and 48 h after infection, respectively, and after 72 h in fibroblasts. 
Experiments involving each mutant were performed at least twice. 
Cell cycle analysis 
Cells were harvested by trypsinization, washed, fixed, stained with 50 mg per mL 
propidium iodide (Sigma), and analyzed as described previously (Jenkins et al., 2011). 
All experiments were performed in triplicate. 
Senescence-associated β-gal staining 
Staining was performed as described previously (Cotter et al., 2007). Briefly, cells 
were fixed in 1% paraformaldehyde and then stained overnight at 37oC in a solution (pH 
6.0) containing potassium ferrocyanide, potassium ferricyanide, and 5-bromo-4-chloro-3-
indolyl-b-Dgalactoside (X-gal). All experiments were performed in triplicate. 
Immunofluorescence 
Cultured fibroblasts were seeded on coverslips in 12-well plates at 30-40% 
confluency, tranduced by lentivirus, and then fixed 72 h post-infection with PBS 
containing 4 % paraformaldehyde for 15 min. Cells were permeabilized with 0.2 %Triton 
X-100 in PBS, then immunostained for 60 min with anti- p16INK4A (1:1000, sc-1661, 
Santa Cruz Biotechnology), followed by a 60 min exposure to Alexa Fluor 594-
conjugated secondary IgG (1:200, A-11062, Life Technologies). Images were captured 
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on a Zeiss Axioskop2 automated microscope, using an Axio Cam MRm camera and 
AxioVision 4.8.1 software (Carl Zeiss Microscopy, Thornwood, NY, USA), and then 
processed with ImageJ software (http://rsbweb.nih.gov/ij/download.html). 
Structural analysis 
Structural modeling of p16INK4A was performed using SwissPdb Viewer 
(http://www.expasy.org/spdbv) as described elsewhere (Guex and Peitsch 1997), based 
on the p16INK4A published structure 1a5e (Byeon et al., 1998). 
Statistics 
Analyses were performed with Prism 3.0 software (GraphPad). Data derived from 
multiple determinations were subjected to two-sided t tests. P values < 0.05 were 
considered statistically significant. Statistical significance is denoted within each figure 
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Inactivation or loss of p16INK4A  is a common event in many tumors types 
(Sharpless and DePinho, 1999), although germ-line mutations in p16INK4A are 
disproportionately associated with melanoma predisposition (Goldstein et al. 2006). The 
p16INK4A protein inhibits the kinase activity of cyclin-dependent kinases 4 and 6, 
preventing the hyperphosphorylation of retinoblastoma-related pocket proteins that are 
required to release E2F transcription factors necessary for cell cycle progression (Lukas 
et al. 1995). Thus the canonical tumor suppressor function of p16INK4A is to prevent 
division of stressed or damaged cells by holding them in the late G1–S transition to allow 
adequate time for DNA repair, or by promoting their irreversible exit from the cell cycle 
into a senescent state (Alcorta et al. 1996). We recently reported a potential novel tumor 
suppressor function for p16INK4A relating to its capacity to regulate oxidative stress. 
Depletion of p16INK4A by RNAi in human cells led to increased levels of intracellular 
reactive oxygen species (ROS) and the elevated levels of oxidative DNA lesion 8-
oxoguanine.  These effects on ROS and 8-OG were independent of the cycle cycle effects 
of p16INK4A (Jenkins et al. 2011). We observed that oxidative dysregulation in p16INK4A -
depleted cells was most profound in melanocytes, compared to keratinocytes or 
fibroblasts. Moreover, in the absence of p16INK4A depletion or exogenous oxidative insult, 
melanocytes exhibited significantly higher basal levels of ROS than these other 
epidermal cell types. Given the role of oxidative stress in melanoma development 
(Meyskens et al. 2001; Cotter et al. 2007; Joosse et al. 2010) we speculated that this 
increased susceptibility of melanocytes to oxidative stress (and greater reliance on 




more commonly associated with predisposition to melanoma rather than other cancers. It 
is not known why melanocytes maintain higher levels of ROS than other cell types, but 
we hypothesized a role for melanin since its presence is a distinguishing feature of 
melanocytes and melanin synthesis is known to generate ROS (Urabe et al. 1994).  
Results 
 
A previous study found a correlation between levels of melanin and ROS, 
showing that both were elevated in melanocytes from dysplastic nevi compared to those 
from normal skin of the same individual (Pavel et al. 2004). Melanogenesis is pro-
oxidative, commencing with the oxidation of L-tyrosine to dopaquinone (Figure 4.1), an 
enzymatic process that can be inhibited by N-phenylthiourea (PTU) (Ito and Watamatsu, 
2008). To evaluate the role of melanin in melanocyte oxidative dysregulation, we derived 
melanocytes and fibroblasts from three separate individuals and cells were cultured in the 
absence or presence of PTU for 14 days. This was sufficient to deplete most of the 
melanin in melanocytes (Figure 4.2a, left). Intracellular ROS levels were then quantitated 
by fluorometric analysis following treatment with the cell-permeable fluorophore 
DCFDA (Jenkins et al. 2011).  As previously reported (Jenkins et al. 2011), melanocytes 
exhibited significantly higher ROS levels compared to donor-matched fibroblasts (Figure 
4.2a, right). By contrast, treatment with PTU resulted in a reduction of basal intracellular 
ROS levels in melanocytes comparable to that of fibroblasts (Figure 4.2a, right). PTU-
treated fibroblasts, on the other hand, showed no significant difference in intracellular 
ROS from their untreated counterparts. 
Next we evaluated the pro-oxidative role of melanin in the context of p16 










Figure 4.1 Intracellular production of melanins. 
brown pheomelanin and the dark brown/black eumelanin involves the hydroxylation of 
tyrosine to DOPA and the oxidation from DOPA to 
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Figure 4.2  Inhibition of melanin synthesis reduces intracellular ROS in melanocytes. (a) 
Human melanocytes were either untreated (-) or treated (+) with 200 µM PTU (Sigma) 
for 14 days (left panel). Endogenous ROS were detected by addition of 20 µM DCFDA 
(Invitrogen) and measured as previously described (Jenkins et al., 2011). Error bars 
represent S.E.M. of triplicate determinations, and results are representative of two 
experiments performed. *P=.003 (two-sided t test). ns, not significant. (b) PTU treatment 
of melanocytes transfected with either a control scrambled (Scr) siRNA sequence, or 
siRNA specific for p16INK4A, decreases melanin content (upper panel). Error bars 
represent S.E.M. of ROS determinations made from three separate donors (middle panel). 
*P= .04, **P=.03 (paired two-sided t test). ns, not significant. Representative Western 

















control or siRNA specific for p16INK4A (Jenkins et al. 2011) to deplete endogenous 
p16INK4A protein (Figure 4.1b, lower panel). Depletion of p16INK4A in both cell types led 
to increases in intracellular ROS, with ROS  levels  consistently  higher  in  melanocytes  
compared  to  fibroblasts  under  both  controlconditions and following p16INK4A 
knockdown (Figure 4.2b, middle). Removal of melanin by PTU (Figure 4.2b, upper) was 
associated with reduction of ROS in melanocytes to levels comparable to fibroblasts, 
even under conditions of p16INK4A depletion (Figure 4.2b). These results implicate 
melanin as the cause of increased oxidative stress in normal and p16INK4A -depleted 
melanocytes. 
Conclusions and Future Directions 
It is established that chronic oxidative stress, and resulting oxidative damage, 
promotes carcinogenesis. Melanocytes are more susceptible to oxidative damage due to 
maintenance of higher levels of ROS (Jenkins et al. 2011). Loss of p16INK4A function 
through methylation-mediated gene silencing, mutation, or gene deletion as is commonly 
found in melanoma (Sharpless and DePinho, 1999), would be predicted to further 
increase ROS levels and correspondingly increase oxidative damage. Elevated levels of 
ROS in melanocytes are likely compounded by the relative deficiency of this cell type in 
the repair of oxidative DNA lesions (Wang et al. 2010). Both acute and chronic UV 
radiation induces ROS in the skin, and we have previously shown that administration of 
the antioxidant N-acetylcysteine prior to and following acute UV exposure delays 
melanoma onset in a mouse melanoma model (Cotter et al. 2007). In this same model 





Although melanocytes may be protected by endogenous melanin which can 
directly absorb UV-generated photons and oxygen radicals (Riley 1997), at higher UV 
doses melanin can be oxidized leading to the generation of ROS (Wood et al. 2006). 
However, we have found in the absence of UV exposure that the pro-oxidative nature of 
melanin production is directly associated with higher melanocyte basal levels of 
intracellular ROS, which increase significantly following p16INK4A depletion. Thus the 
presence of melanin in the skin appears to be a double-edged sword: it protects 
melanocytes as well as neighboring keratinocytes in the skin through its capacity to 
absorb UV radiation, but its synthesis in melanocytes results in higher levels of 
intracellular ROS that may increase melanoma susceptibility. Several addition 
experiments can be performed to enhance our understanding of the exact role 
melanogenesis is playing in constitutively increasing intracellular ROS.  For example, 
alternative methods can be used to inhibit both pheomelanin and eumelanin production, 
such as RNAi against tyrosinase. Additionally, one could use RNAi to inhibit TRP-1 
and/or TRP-2, which are selective for the synthesis of eumelanin, in order to parse out 
any differential effects on intracellular ROS through the synthesis of eumelanin versus 
pheomelanin. 
Materials and Methods 
Treatment of cells with N-phenylthiourea 
We derived melanocytes and fibroblasts from three separate individuals as  
previously described (Jenkins et al. 2011) and cells were cultured in the absence or 




were than harvested via trypsinization, pelleted at 1200 RPM for 5 minutes, washed with 
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This dissertation overviews experimental designs and discoveries that were driven 
by the hypothesis that the familial-melanoma predisposition gene p16INK4A functions to 
regulate intracellular oxidative stress independently of its canonical role as a regulator of 
the G1/S transition of the cell cycle.  Previous work in our lab has demonstrated that 
reducing oxidative stress in a highly-penetrant melanoma mouse model delays the 
formation of melanoma (Cotter et al. 2007).  Also, excessive UVR exposure, widely 
accepted to be the most important environmental contributing factor in melanoma, is 
thought to induce its melanomagenic effects through excessive ROS production (Herrling 
et al. 2006, Kripke 1994, Noonan et al. 2001, Meyskens et al. 2001).  These previous 
observations led us to investigate whether this most important environmental factor was 
intimately associated with a very important genetic factor in melanomagensis; that is 
whether p16INK4A was functioning to regulate aberrantly high levels of intracellular ROS.  
Using multiple in vitro and in vivo approaches, we observed that p16INK4A depletion or 
deficiency leads to dysregualtion of intracellular oxidative stress, and an increase in 
potentially mutagenic oxidative DNA lesions (Jenkins et al. 2011).  Due to the inherently 
pro-oxidative effect of melanin production that we observed, melanocytes seem 
especially sensitive to these aberrantly high levels of intracellular ROS and oxidative 
lesions. Taken together, these data implicate p16INK4A as a possible bipartite tumor 
suppressor that is not only necessary to prevent the formation of potentially mutagenic 
lesions through this newly-discovered intracellular oxidative stress regulatory function, 
but also is necessary to act as a G1/S transition checkpoint of the cell cycle, allowing 




propagation of these errors into future cellular generations (Jenkins et al. 2011). This may 
also give rationale as to why melanocytes seem especially sensitive to oncogenic 
transformation compared to other cell types in the context of p16INK4A compromise.  
Perhaps there is a threshold of intracellular oxidative dysregulation necessary to promote 
oncogenesis, and the constitutively higher levels of ROS observed in melanocytes due to 
their unique burden of producing melanin lend them to being more easily pushed above 
that threshold when the antioxidant effect of p16INK4A is negated. 
 Many mutations in the p16INK4A coding sequence can potentially alter the 
sequence of both p16INK4A and ARF, yet our analysis shows that murine fibroblasts 
nullizygous for both these genes were able to have regulation of intracellular ROS 
restored upon  re-expression of just p16INK4A, signifying both its necessity and sufficiency 
to regulate this novel pathway. This observation seems to be recapitulated in patient 
samples with regard to p16INK4A being more important for tumor development than ARF, 
as specific somatic loss of p16INK4A has been reported in thousands of human cancers 
(Forbes et al. 2006).  Also, unrelated kindreds that are predisposed to various forms of 
cancer have presented at least 56 unique germline mutations in p16INK4A that do not affect 
ARF (Greenblatt et al. 2003). 
A high percentage of mutations associated with familial melanoma span the 
coding sequences that do not seem to cluster in discernible “hot spots” (Greenblatt et al. 
2003).  These observations combined with our novel discovery of an alternative function 
of this protein lead us to hypothesize that several of these mutations may differentially 
affect the two functions of cell-cycle and oxidative stress regulation, and in some cases 




completely restore ROS regulation or cell cycle arrest while showing a complete 
dysregulation of the other function.  To this end, a panel of familial melanoma-associated 
point mutants were constructed via overlap mutagenic PCR and these constructs were 
expressed at consistent levels in murine fibroblasts nullizygous for p16INK4A.  
Interestingly, we were able to segregate the phenotypes exhibited by these mutant 
constructs of p16INK4A into four functional groups using a cutoff value of 30% of wild-
type activity as qualifying as competent to restore function.  We classified mutants as 
unable to restore either oxidative or cell cycle regulation (R87W, L97R, P81T), mutants 
that selectively restored oxidative regulation (R99P, V126D, R24Q), mutants that 
selectively restored cell cycle regulation (A36P, A57V, P114S), and mutants that restored 
both oxidative and cell cycle function (R24P, G35A, G35V).  The cell cycle  regulatory 
ability observed for these mutants in our system largely agreed with previous studies in 
the literature that involved slightly different experimental systems (McKenzie et al. 2010, 
Jones et al. 2007, Kannengiesser et al. 2009, Becker et al. 2001, Miller et al. 2011, Spica 
et al. 2006, Debniak et al. 2005, Goldstein et al. 2008).  However, our system was 
optimized with several advantages over what has been performed previously when 
functionally characterizing these mutants.  Whereas several previous studies utilized 
various cancer cell lines that were null for the entire CDKN2A locus (McKenzie et al. 
2010, (Jones et al. 2007, Miller et al. 2011) we performed the exogenous expression of 
our p16INK4A constructs in a primary fibroblast line selectively null for p16INK4A, thereby 
limiting the potential for confounding effects elicited by oncogenic background mutations 
in the tumor lines.  Careful titration work was also performed to ensure the level of 




physiological levels natively seen in wild-type cells as well as nearly identical between 
mutants.  This level of consistency of expression was rarely observed in other functional 
studies of candidate p16INK4A mutations, as the proteins of interest were often grossly 
overexpressed.  The careful, consistent expression levels of these familial melanoma-
associated p16INK4A mutants  potentially allows us to get a more accurate representation 
of the events involved with initiation of melanomagenesis in the affected families.    
Future Directions for Classifying p16INK4A-mediatedIntracellular 
  Oxidative Stress Regulation as a True 
Novel Tumor-Suppressor Function 
It is widely accepted that excessive intracellular oxidative stress is oncogenic due 
in a large part to oxidation of DNA, which in turn can lead to genomic instability (Waris 
and Ahsan 2006).  Our study demonstrates through several in vitro modalities that 
compromise of p16INK4A can lead to excessively high intracellular ROS and oxidative 
stress (Jenkins et al. 2011).  However, we have yet to show that oxidative regulatory 
activity of p16INK4A is truly tumor-suppressive in vivo.  Recently, new in vivo melanoma 
models have been developed which may allow for the rapid validation of regulation of 
oxidative stress as a tumor suppressor function.  For example, VanBrocklin et al. (2010) 
recently developed a highly penetrant melanoma mouse model that utilizes a somatic 
gene delivery system that facilitates the rapid validation of genetic alterations that occur 
during disease development.  These mice are engineered to express the tumor virus A 
(TVA) receptor that is under the control of the dopachrome tautomerase (DCT) promoter, 
which ensures that only melanocytes will express the receptors for members of the avian 




Sarcoma virus (RSV), in which the region encoding src has been replaced by a gateway 
cassette that can be used to express one or more oncogenic genes of interest (known as an 
RCAS vector). The DCT-TVA mice are crossed to p16INK4A/Arflox/lox mice, so that the 
resulting DCT-TVA/ p16INK4A/Arflox/lox mice are primed to have RCAS introduce linked 
NRAS and Cre expression into in vivo melanocytes nullizygous for p16INK4A to insure a 
basal melanoma rate of 60-70%.  We potentially could use these mice as a positive 
control for melanoma development that is dependent on deficiency of p16INK4a, the same 
way we used murine fibroblasts cultures as a positive control for cell cycle and oxidative 
stress dysregulation in our in vitro model.  We could then treat a subset of these mice 
with a virus that expressed an RCAS consisting of NRAS linked with Cre as well as our 
individual familial melanoma-associated point mutations of interest.  By expressing 
p16INK4a mutants that were found to selectively dysregulate either oxidative stress or cell 
cycle, we could theoretically score the individual contribution that each dysregulated 
phenotype has in tumorigenesis.  This system would also allow us to test the p16INK4a 
constructs that did not dysregulate either oxidative stress of cell cycle to observe whether, 
and to what extent, they are tumorigenic in this mouse model.   
In theory, it would also be of great clinical relevance to use this newly-discovered 
data to observe patient samples stemming from families that harbor the familial 
melanoma-associated point mutations in p16INK4A.  Cells derived from such tumors could 
be analyzed for intracellular ROS versus cell cycle dysregulation compared to donor-
matched melanocytes; this could give more accurate insight into what role each of these 
putative suppressor functions contributes to melanomagenesis in human patients. Also, 




metastasis in patients that harbor different germline mutations in p16INK4A, and then 
compare that score with oxidative versus cell cycle phenotype.  However, this type of 
patient analysis is not currently feasible given the extremely low number of families that 
have been identified with these mutations of interest, and the low amount of tumor 
material therefore that could be analyzed from these given families would most likely not 
yield enough data points for a statistically significant stratification of oxidative and cell 
cycle deregulatory phenotypes.  Our observations, however, can easily be extended to 
what is most commonly seen in melanoma.  Most melanoma cell lines are null for 
CDKN2A, brought about mostly through promoter methylation mediated by BMI-1 and 
Polycomb Repressor Complex 1 and 2 (Molofsky et al. 2003, (Lessard and Sauvageau 
2003, Park et al. 2003, Jacobs et al. 1999).  Melanoma lines have been observed to 
produce higher levels of intracellular ROS than normal melanocytes (Pavel et al. 2004), 
and our data would suggest that perhaps this phenotype in caused at least in part through 
a lack of p16INK4A-mediated oxidative stress regulation that is truly independent of the Rb 
pathway and cell-cycle regulation, and that reestablishment of p16INK4A expression in 
these lines could at least partially normalized cell cycle and oxidative stress regulation 
(Jenkins et al. 2011). 
Cellular senescence is a state of permanent growth arrest that serves as a barrier 
against tumorigenesis.  Senescence is known to involve the upregulation of p16INK4A and 
is induced through a number of mechanisms such as DNA damage, telomere attrition, 
oxidative stress, and aberrant signals from known oncogenes (such as oncogenic RAS) 
(Collado and Serrano 2006).   In light of our observations, it would be interesting to test 




extent, they retain their ability to induce senescence under various conditions, such as 
prolonged time in cell culture or expression of oncogenic RAS signaling.  These studies 
could shed light on whether the putative tumor suppressor mechanism of senescence 
induced by p16INK4A was being compromised, and if senescence regulation could be 
uncoupled from the other described functions of p16INK4A, cell cycle and oxidative stress 
regulation. 
Future Directions to Identify Novel Binding Partners  
and Mechanistic Pathways of p16INK4A 
The discovery of a novel, potentially tumor-suppressive function of p16INK4A that 
is independent of its canonical cell-cycle regulatory role is very exciting in the context of 
better elucidating the complex signaling occurring during melanomagenesis.  This work 
underscores the importance of continued investigation into possible alternative signaling 
pathways for even the most well-defined tumor suppressors.   
Recent studies have presented evidence of the existence of even more potentially 
tumor-suppressive functions of p16INK4A, and presents possible pathways with which 
p16INK4A interacts to regulate intracellular oxidative stress.  The expression of a 
chromatin remodeling factor, brahma-related gene 1 (BRG-1) is frequently lost in 
primary and metastatic melanomas (Becker et al. 2009).  It has been observed that 
p16INK4A interacts with BRG-1 (Becker et al. 2009), but the functional consequences 
remain unclear.  As chromatin remodelers have the capacity to globally affect 
transcription, perhaps p16INK4A affects the expression levels of many different proteins 
through this relatively understudied interaction.  The RAS-JNK-Jun-AP-1 signaling 




increased oxidative stress when activated.  It has been observed that p16INK4A can bind to 
JNK 3, and block UV-induced phosphorylation of c-Jun that occurs through the RAS-
JNK-Jun-AP-1 signaling pathway (Choi et al. 2005).  One could test whether this 
p16INK4A-induced inhibition of this pathway serves to regulate oxidative stress, and 
inhibit melanonagenesis, especially since it is occurring in the context of UV-exposure. 
In breast cancer cell lines, overexpression of p16INK4A decreases the expression of 
vascular endothelial growth factor (VEGF) (Zhang et al. 2010).  VEGF is an important 
inducer of angiogenesis, and is essential for tumors to grow beyond a microscopic size.  
It was found that p16INK4A binds to hypoxia-inducible factor-1 α (HIF-1α), a critical 
subunit of the transcriptional activator of the VEGF gene (Zhang et al. 2010), thereby 
potentially altering the ability of HIF-1α to transactivate VEGF expression.  Potentially 
p16INK4A could be regulating intracellular oxidative stress through inhibiting HIF-1α, 
since several transcriptional targets of HIF-1α have the potential to increase ROS levels.  
It would also benefit the field to analyze whether this interaction is unique to breast 
cancer, or if this p16INK4A-HIF-1α pathway is present in melanoma. 
In light of our novel observation that p16INK4A can regulate intracellular oxidative 
stress, in may be of great relevance to re-analyze the role of p16INK4A and its interactions 
in these other potentially oncogenic pathways.  It would also be of great interest to 
analyze different familial melanoma-associated point mutations in p16INK4A to observe 
any effect the compromise of different residues has on the binding of different classes of 








The discovery of alternative, potentially anti-oncogenic roles of established 
tumor-suppressor proteins is an exciting area of biology.  Advances in the elucidation of 
potential secondary or tertiary roles for these well-studied proteins that are yet to be 
discovered could lead to a more comprehensive understanding of the signaling networks 
involved in oncogenesis.  Understanding mechanisms and pathways at this level would 
allow for the design of more potent and specific inhibitors of dysregulated pathways, as 
well as decreasing the potential for off-target effects. Our observation that different cases 
of familial melanoma involving different mutations in the predisposition gene p16INK4A 
may potentially exhibit nuanced differences in the initiating events of their cancers may 
eventually lead to much more effective prophylactic prevention, diagnosis, and treatment 
for affected individuals based on their own specific genetic disposition. 
The studies presented here also potentially have much larger implications that 
extend well beyond the role of p16INK4A and melanomagenesis.  As mentioned 
previously, the ankyrin repeat protein family contains approximately 3,600 members 
identified by the nonredundant SMART protein database (Mosavi et al. 2004), and are 
involved in a diverse array of functions as transcriptional regulation, cytoskeleton 
organization, cell cycle progression, cell development, and differentiation (Sedgwick and 
Smerdon 1999, Michaely et al. 2002).  Our observations demonstrate that the target 
selection by ankyrin repeat proteins in general may not be as strict as previously thought, 
and despite the wide array of biological functions known to be performed by these 
proteins, perhaps many more have alternative disease suppressing functions that remain 
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